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The most important primary headaches are migraine. Migraine has a prevalence of 10% in the general 
population and its societal costs are high. The precise mechanisms underlying the pathophysiology of 
migraine are still elusive. Nitric oxide (NO) is believed to play a key role in migraine pathogenesis. In 
this study, we compared migraine patients with healthy controls by measuring plasma nitrite levels in 
order to investigate the effects of nitric oxide in migraine patients during headache free and attacks 
period. A total of 26 patients with migraine in headache free period and 24 patients with migraine in 
attack period participated in our study. Control group consisted of 24 healthy subjects. Plasma NO 
levels were measured spectrophotometrically. Plasma nitrite levels were found significantly higher than 
controls during headache free period (p < 0.05). By contrast, it was found significantly decreased in 
attack periods compared to headache free period. No significant change in plasma nitrite levels in 
migraine attacks period compared to controls was observed (p > 0.05). Plasma nitrite levels were not 
altered significantly after an attack in the patients with migraine. These results suggested that 
increased level of plasma NO during headache free period may play an important role in migraine 
pathogenesis. 
 
Key words: Headache, migraine, nitric oxide, oxidative stress. 
 
 
INTRODUCTION 
 
Migraine is a common, chronic and disabling neurovascu-
lar disorder that is characterized by severe headache 
attacks with photophobia, nausea, vomiting, autonomic 
symptoms, and in some patients with aura involving 
neurological symptoms (Uzar et al., 2011). Migraine is 
the most prevalent neurological disorder, with an esti-
mated 43 million sufferers in Europe and slightly smaller 
numbers in the USA (Andlin-Sobocki et al., 2005; Lipton 
et al., 2007). It is a very painful condition that often leads 
to absenteeism from work and more often to considerably 
decreased efficiency at work. The estimated cost of 
migraine in  Europe  is  €27,000  million  per  year  which,  
among the neurological disorders, ranks third after 
dementia and stroke (Andlin-Sobocki et al., 2005). 
Migraine is considered to be a disorder of neurovascular 
transmission without structural lesions (Olesen et al., 
1993).  
The molecular mechanisms of migraine have not been 
fully clarified yet. It has been hypothesized that increased 
oxidative and nitrosative stress may together take place 
in patients with migraine, especially during attacks 
(Yilmaz et al., 2007). There are many theories about the 
pathophysiology of migraine attacks. Most of these in-
volve hereditary (Alexandrea, 1998; Lance  and  Goodsby, 
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1998). Biological states that may cause increases in free 
fatty acids and blood lipids increased platelet aggrega-
tion, decreased serotonin levels and increased prosta-
glandin levels (Bic et al., 1998). Such changes can cause 
the vasodilatation that precedes migraine headache 
(Alexandrea, 1998; Bic, 1998).  
Before the pain attack, cerebrovascular spasm induced 
by factors such as menstruation, lack of sleep, skipped 
meals, allergic reaction, and physical or mental stress, 
among others initially causes ischaemia which, in turn, 
produces prodromal symptoms such as nausea, 
photophobia or phonophobia (Alexandrea, 1998; Lance 
and Goodsby, 1998; Sadovsky, 1998). 
Nitric oxide (NO) is a gaseous mediator synthesized 
mainly in the endothelium that exerts many important 
regulatory functions on the vessel wall and platelet 
(Moncada et al., 1991). NO can play a modulatory role on 
biological processes such as vasodilatation in migraine 
attacks (Bellantonio et al., 1998; Olesen, 1993). It has 
also been reported that NO can be released from 
endothelial cells, neurons, macrophages, and platelets. 
Because human platelets contain an L-arginine/NO 
pathway which may be associated with platelet aggrega-
tion (Radomski et al., 1990), NO may play a role in the 
pathogenesis of migraine and other vascular headaches. 
The final products of NO in vivo are nitrite (NO-2) and 
nitrate (NO-3), but the relative proportions of nitrite and 
nitrate are variable (Moncada et al., 1991). The best 
index of overall NO production, therefore, is the total 
concentration of both nitrate and nitrite (total 
nitrate/nitrite). 
In our study, we compared migraine patients with 
healthy controls by measuring plasma nitrite levels in 
order to investigate the effects of nitric oxide in migraine 
patients during headache free and attacks period. 
 
 
MATERIAL AND METHODS 
 
Patients 
 
In our hospital-based case-control study, 26 patients with migraine 
in headache free period and 24 patients with migraine in attack 
period participated. 24 controls without migraine diseases were 
recruited. The diagnosis of headache was made in accordance with 
the International Headache Society (IHS) criteria (Olesen, 2008). 
The migraine patients in headache free period group consisted of 
26 subjects. The mean age was 33.3 ± 6.3 years [mean ± standard 
deviation (SD)]. The migraine patients in attack period group 
consisted of 24 subjects. The mean age was 31.4 ± 4.9 years 
(mean ± SD). The 24 normal controls without migraine diseases 
were recruited; the mean age was 30.1 ± 4.1 years (mean ± SD). 
Written informed consent was obtained from all subjects.  
The study was carried out in the neurology clinic of Firat 
University Research and Application Hospital. Patient and healthy 
volunteers were recruited from the Department of Neurology, 
University of Firat. Furthermore, this study was approved by the 
Ethics Committee of the Medical Faculty of the same university. 
Medical, neurologic, and psychiatric evaluations were made on all 
of the patients. Patients having these characteristic were  excluded;   
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first-axis psychiatric disorder now or in the past, history of alcohol 
and cigarette consumption, history of any kind of medicine 
consumption within the last 2 weeks prior to the study (except 
simple analgesic), neurologic disorder and/or symptom in clinic and 
history, history of head trauma, history of cardiovascular, renal and 
endocrinologic disorder and existing medical disorder.  
 
 
Measurement of plasma nitrite  
 
Venous blood samples were taken from the antecubital vein with 
suitable vacutainers with ethylenediaminetetraacetic acid (EDTA) 
as anticoagulant. The basal venous blood was obtained from all the 
participants in this study on the morning after 12 h of overnight 
fasting. In all cases, blood samples were taken according to the 
principles of the Helsinki declaration. The blood samples were 
drawn from the patients. These samples were centrifuged at +4°C 
at 3,000 rpm for 10 min, and after separating plasma they were 
kept at -20°C until analysis. Among all participants, information on 
demographic characteristics and risk factors was collected using a 
structured questionnaire. NO measurement is very difficult in 
biological specimens because it is easily oxidized to nitrite (NO2) 
and subsequently to nitrate (NO3) which serve as index parameters 
of NO production. Samples were initially deproteinized with NaOH 
and ZnSO4. Total nitrite (NO2 to NO3) was measured by 
spectrophotometer at 545 nm after conversion of NO2 to NO3 by 
assay reactive. A standard curve was established by a set of serial 
dilutions of sodium nitrite. Results were expressed as µmol/L per 
plasma (Lyall et al., 1995). 
 
 
Statistical analysis 
 
The statistical package for the Social Sciences (SPSS) 15.0 (SPSS 
Inc, Chicago, IL, USA) was used for statistical analysis. The plasma 
NO levels were evaluated statistically by Mann-Whitney U test. 
Results were given as mean ± SD, and p < 0.05 was accepted to 
indicate  significant levels.  
 
 
RESULTS 
 
In control group, plasma nitrite levels were found to be 
85.8 ± 3.2 µmol/L. In migraine patients, plasma nitrite 
level was detected to be 95.9 ± 21.2 µmol/L during head-
ache free period and 85.2 ± 2.7 µmol/L during attacks. 
According to our results, slightly higher levels of nitrite in 
plasma of migraineurs during headache free period were 
found than in control subject. A statistically significant 
difference was observed in  plasma nitrite level  between 
migraine patients and control groups (p = 0.004). The 
plasma nitrite values of the patients and control groups 
are shown in Table 1. 
When the patients were grouped as migraineurs with in 
headache free period and in attack period, plasma nitrite 
levels were significantly decreased in attacks periods 
compared to headache free period (p < 0.05). No 
significant change in plasma nitrite levels in migraine 
attacks period compared to controls was observed (p > 
0.05). The plasma NO values in the attack period and 
initial period in migraine patients are shown in Table 2 
and Figure 1. 
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Table 1. The values of plasma nitric oxide in migraine patients and control groups.  
 
Variable Control group (n=24) 
Patient 
(n=26) 
Total 
(n=40) p 95% CI 
Age (years) 30.1±4.1 33.3±6.3 31.6±5.2 0.287 0.488-0.283 
Nitric oxide 85.8±3.2 95.9±21.2 89.29±13.3 0.004* 23.090-2.76 
 
*p < 0.05 as significant level. CI = confidence interval. 
 
 
 
Table 2. The values of plasma nitric oxide in the attack period and initial period in migraine 
patients. 
 
Variable Control group (n=24) 
Patient 
(n=26) 
Migraine during attack 
(n=24) 
Age (years) 30.1±4.1 33.3±6.3 31.4±4.9 
Nitric oxide 85.8±3.2a 95.9±21.2b 85.2±2.7a 
 
a,bp < 0.05 as significant level.  
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Figure 1. The distribution of values of plasma nitric oxide in the study groups. Group 1: 
healthy control (n = 24), Group 2: migraine patients in initial period (n = 26), Group 3: 
attack period (n = 24).  
 
 
DISCUSSION 
 
Migraine is a chronic disease with frequent attacks, high 
levels of pain and disability during attacks which causes 
reduced quality of life between attacks (Yilmaz et al., 
2007). It is a widespread disorder, affecting about 10 to 
15% general population. However, the mechanisms 
underlying the disease have not been clearly understood. 
Vascular disturbance in intracranial arteries plays a 
significant role in the migraine attacks. It was suggested 
that hemodynamic changes during the migraine attacks 
may be related to alterations in the level of NO. NO can 
precipitate  the attacks by causing vasodilatation in 
cerebral vessels. It was shown that platelet hyperaggre-
gation has an important role in migraine pathophysiology. 
Aggregated platelets produce  NO  levels  which  show  a  
  
 
 
 
 
counter effect to vasoconstrictors and finally cause 
vasodilatation and prevention of platelet aggregation 
(Yilmaz et al., 2007). 
In our study, we measured NO activity during headache 
and headache-free period in migraine patients. Since NO 
is rapidly oxidized by tissue oxygen to the stable end 
products, nitrate (NO3-) and nitrite (NO2-), the best index 
of overall NO production is the total concentration of both 
nitrate and nitrite. Therefore, we measured total nitrite 
levels as an indicator of NO production. As similar to pre-
vious studies (D'Andrea and Cananzi, 1994; Sarchielli et 
al., 1996; Shimomura et al., 1999; Uzar et al., 2011), we 
found that plasma nitrite levels were significantly higher in 
migraine patients during headache-free period. 
Shimomura et al. (1999) showed that NO level decreased 
in headache-free period of migraine patients. In contrast 
to this study, we found slightly higher nitrite levels in 
headache-free period of migraine patients. In the light of 
our findings, we concluded that NO may be produced in 
plasma during headache-free period and increased NO 
may be related to the changes in the vascular vessels 
and pain during headache-free period. We would like to 
suggest that when the NO levels exceed a critical level, 
the headache-free period may begin.  
On the other hand, simultaneous release of NO and of 
superoxide anions produces peroxynitrite anion which is 
a strong biological oxidant known to oxidize lipids, 
proteins and sulfhydryl (SH) groups particularly. In the 
most recent study on this issue, Taffi et al. (2005) eva-
luated platelet peroxynitrite levels a metabolite of nitric 
oxide as well as a potent oxidant in migraine patients to 
resolve uncertainty about NO activity in headache free 
period. They found increased peroxynitrite levels during 
headache-free period which are in concordance with our 
results. The main reason of increased peroxynitrite 
concentrations is concomitant overproduction of NO and 
superoxide anion, and these changes may result from 
platelet hyperaggregation. Therefore, increased nitro-
sative and oxidative stress may influence platelet function 
and cerebral microcirculation. It was suggested that NO 
may cause the headache through variations of cerebral 
blood flow by interacting with oxygen free radicals in 
migraine (Ciancarelli et al., 2003). It has also been pro-
posed that NO may be involved in the pathophysiology of 
naturally occurring headaches such as migraine 
(Thomsen et al., 1993; Lassen et al., 1995). However, as 
of yet, there is no evidence that NO levels in the brain are 
elevated during the headache phase of migraine in 
humans (Lassen et al., 1997). 
NO is one of the indicators of oxidative stress (Yilmaz 
et al., 2007). NO, a labile molecule with a half life of only 
a few seconds is synthesized generally in the 
endothelium. It is rapidly oxidized by tissue oxygen to the 
stable end products, nitrate and nitrite.  Therefore, to the 
best index of overall NO production in the circulation is 
the total concentrations of both nitrate and nitrite  (Yilmaz  
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et al., 2007; Tain el al., 2010). NO is one of the 
substances that takes part in the pathophysiology of 
migraine (Yilmaz et al., 2007). NO is involved in the 
regulation of the cerebral vessels tone. NO may function 
as a signaling molecule in controlling neuronal activity 
and is important in controlling sensory inputs during 
migraine attack and interacting with reactive oxygen 
substances (ROS) which may induce headache through 
changes of cerebral blood flow (Ciancarelli et al., 2005).  
The most important effect of NO is the activation of the 
soluble guanylate cyclase. This enzyme causes the syn-
thesis of cyclic guanosine monophosphate (cGMP), and 
nitric oxide-cyclic guanosine monophosphate (NO-cGMP) 
pathway in smooth vascular muscles causes vascular 
dilation and relaxation (Olesen, 2008; Napoli et al., 2009). 
It is suggested that NO could be an important mediator in 
the initiation or the propagation of a neurogenic cranial 
vessel inflammatory response that might eventually result 
in a migraine attack (Napoli et al., 2009).  
It has been found that the pathways consisting of NO 
synthesis are activated in the experimental headache 
models such as nitroglycerin-induced headache 
(Sarchielli et al., 2000). The increase of NO may be 
caused by interactions with free ROS. The primary pro-
duct of the interaction between NO and superoxide anion 
is peroxynitrite. Peroxynitrite is an aggressive and potent 
cellular oxidant (Gruber et al., 2009). So, increased NO 
with migraine patients may be associated with oxidative 
stress. In addition, occurrence of peroxynitrite following 
NO increases the effects of endothelia function 
(Fo¨rstermann, 2008). Marked NO increase in migraine 
group in our study strengthened the correlation between 
oxidative stress and endothelia dysfunction in 
pathophysiology of migraine. The findings of increased 
NO in migraine may lead to new therapeutic strategies, 
including probable antioxidant use for management of 
migraine. In the future, development and enhancements 
of existing drugs may be accompanied by increased 
efforts to develop truly new migraine drugs based on 
knowledge of the pathophysiology (Stovner et al., 2009; 
Farinelli et al., 2009). 
 
 
Conclusıon 
 
Results obtained indicate that the plasma nitrite levels 
were not altered significantly after an attack in the 
patients with migraine. Nitrosative and oxidative stress 
are increased during headache-free period in plasma. 
Increased oxidative damage together with increased NO 
level in migraine attack may effect cerebral blood flow 
and cause headache. These results suggested that in-
creased level of plasma NO during headache free period 
may play an important role in migraine pathogenesis, and 
NO may serve as useful markers to show the increased 
oxidative stress in migraine patients. Further  clinical  and 
  
826          Afr. J. Pharm. Pharmacol. 
 
 
 
biochemical studies are needed to investigate the 
associations between migraine, stroke and to introduce 
new therapeutic modalities for migraine treatment. 
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This study evaluated the in vitro physico-chemical implication of co-presentation of ciprofloxacin with 
artesunate. Thin layer chromatography (TLC) and ultraviolet (UV) analysis was used to monitor the co-
presentation of the two drugs. The in vitro dissolution profile of ciprofloxacin hydrochloride tablet in 
the presence of artesunate tablet was evaluated in buffer with pH 1.2 and water at 37± 0.5°C as well as 
the effect artesunate on the antibacterial activity of ciprofloxacin. Physico-chemical interaction was not 
observed between ciprofloxacin and artesunate. However, a significant reduction in the dissolution rate 
of ciprofloxacin was observed in buffer pH 1.2 solution when compared with water as the medium (p< 
0.01). Furthermore, the rate of dissolution of ciprofloxacin was significantly reduced in the presence of 
200 mg artesunate in both media (p = 0.0164). Similarly, the extent of drug release at 30 min (C30) was 
generally reduced in the presence of 200 mg artesunate in both water and buffer pH 1.2 solution (p < 
0.05). The reduction in antimicrobial activity of ciprofloxacin on clinical isolates of Staphylococcus 
aureus and Escherichia coli was observed to be statistically insignificant in the presence of artesunate 
(p > 0.05). The results obtained in this study suggest that care should be taken during the co-
administration of ciprofloxacin with the starting dose of artesunate.  
 
Key words: Ciprofloxacin, artesunate, physico-chemical interaction, dissolution rate, Staphylococcus aureus 
and Escherichia coli. 
 
 
INTRODUCTION  
 
Ciprofloxacin [1 cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-
(1-piperazinyl)-3-quinoline carboxylic acid], is one of the 
quinolone antibiotics which is a class of highly potent and 
orally active broad spectrum antibacterial compounds 
developed from the original 1,8-napthyridine urinary 
antibacterial agent, nalidixic acid (Smith et al., 1990). 
Ciprofloxacin is indicated for both Gram-negative and 
Gram- positive bacterial infections. It has been used in 
the treatment of a wide range of infections including 
biliary-tract infections, bone and joint infections, acute 
bacterial infections, gastro-enteritis, gonorrhea, immuno-
compromised patients (neutropenia), skin disorders, 
typhoid and paratyphoid fever and urinary-tract infection 
(UTI) (Martindale, 2009). Ciprofloxacin have been 
reported to inhibit DNA gyrase activity, thereby causing 
significant antiparasitic  effect  against  various  strains  of 
Plasmodium falciparum malaria (Mahmoud et al, 2003; 
Yeo and Rieckmann 1994). Malaria, a parasitic protozoal 
disease, is one of the most serious complex and 
refractory health problems currently facing humanity. The 
co-presentation of microbial infections and malaria is not 
uncommon in tropical developing countries, thus, the co- 
administration of antimicrobial drugs with antimalaria is a 
common practice. The co-administration of two or more 
drugs is usually accompanied by a variety of therapeutic 
implications ranging from opposition, alteration, sy-
nergism, potentiating as well as physical and chemical 
antagonism (Olaniyi, 2000). 3R,5aS,6R,8aS,9R,-10S,-
12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H 
pyrano(4,3-j)-1,2-benzodioxepin-10-ol hydrogen Artesunate, 
chemically known as (3R,5aS,6R,8aS,9R,10S,12R,12aR)-
decahydro-3,6,9 trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-  
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1,2 enzodioxepin-10-ol hydrogen succinate, is a 
derivative of artemisinin which have been found useful in 
chloroquine-resistant malaria (O’Neill et al., 2010). 
Artesunate is about the most widely used of the 
artemisinin derivatives and is a key member of all the 
artemisinin combination therapies (ACT) compositions re-
commended by World Health Organization (WHO) for the 
management of malaria presently (WHO, 2006). The co-
administration of ciprofloxacin with a variety of drugs has 
been reportedly accompanied with varied pharmacolo-
gical effects. Probenecid was reported to increase the 
plasma concentration of ciprofloxacin as a result of a 
reduction of its excretion (Lim et al., 1995). Cyclosporine 
increases risks of nephrotoxicity when used 
concomitantly with ciprofloxacin (Van et al., 1990), while 
non-steroidal anti-inflammatory drugs (NSAIDs) and 
theophylline possibly increases risk of convulsion with 
ciprofloxacin (Polk, 1989). Antacids, calcium salts, 
sucralfate, zinc and oral iron reduce the absorption of 
ciprofloxacin; this may result in decreased plasma 
concentration (Taxeira et al., 1995; Joint Formulary 
Committee, 2003).   
The possibility of decreased solubility resulting in de-
creased absorption as a result of physical interaction due 
to adsorption of drug particles has been reported (Galia 
et al., 1998). Similarly, chemical interactions in form of 
oxidation, hydrolysis, etc. of two or more drugs may result 
in significant effect on the therapeutic activity of the drug 
compounds (DiPalma, 1976). The co-administration of 
ciprofloxacin with antimalaria agents such as chloroquine 
and artesunate during the management of bacterial 
infection co-presented with malaria as a result of its 
broad spectrum of activity formed the basis for this study. 
In this study, the effects of artesunate on the dissolution 
profile and antimicrobial activity of ciprofloxacin against 
two strains of Staphylococcus aureus and Escherichia 
coli were determined.   
 
 
MATERIALS AND METHODS  
 
Materials and equipment 
 
Ciprofloxacin hydrochloride powder was donated by Gemini 
Pharmaceuticals, Lagos, Nigeria, while artesunate powder was 
donated by Bond Chemical Industries Ltd, Awe, Oyo State, Nigeria. 
Artesunate tablet (50 mg) manufactured by Makophar Chemical 
Pharmaceutical Company Vietnam and ciprofloxacin HCl tablets 
(500 mg) manufactured by V.S. International PVT.LTD were 
obtained from retail pharmacy outlets in Ibadan. All the reagents 
used were of analytical grade. 
UV Spectrophotometer (UNICAM) was use for drug content 
quantization, while Langford ultrasonics sonomatic® water bath and 
dissolution test apparatus USP standard were used for the 
interaction studies. The microbiological assay was carried out using 
Fisher Isotemp 
(R)
 200 series incubator and Equitron autoclave 
carried out by determining the melting point, UV spectra between 
200 to 400 nm. The chemical content were determined using the 
official method for artesunate (I.P. 2003), while an earlier reported 
method with very good interday and intraday precision was used for 
ciprofloxacin HCl samples (Adegbolagun et al., 2007).  
 
 
 
 
Physico-chemical interaction evaluation 
 
Ultraviolet spectroscopy 
 
Stock solutions of ciprofloxacin HCl (5 mg/ml) (CIP) and artesunate 
(1 mg/ml) (ART) were prepared in buffer pH 1.2. Aliquot 
concentrations; 1000 µg/ml of CIP, 100 and 200 µg/ml of artesunate 
(ART) were prepared from the stock solutions. Solutions of the two 
drugs were combined at the following ratios to give a final 
concentration of; ART: CIP (50: 500 µg/ml and 200: 500 µg/ml), 
also individual solutions at ART (50 and 200 µg/ml) and CIP (500 
µg/ml) were transferred into six labeled covered test-tubes per 
reaction mixture. The test tubes were placed in thermostated water 
bath at 37± 0.5°C. UV spectra (200 to 400 nm) of each set of the 
reaction mixture were run at 0, 15, 30, 45, 60 and 90 min using the 
buffer pH 1.2 as blank. The determination was carried out in 
duplicate. The procedure was repeated in distilled water. 
 
 
In vitro dissolution profile evaluation 
 
UV absorbance of solutions of CIP (0.1 - 5 × 10
-4
%w/v) at 276 nm 
was used to generate a calibration curve of CIP in buffer pH 1.2 
and distilled water. In vitro dissolution profile of CIP was determined 
according to B.P. 2010 method (British Pharmacopoeia, 2010). The 
determination was carried out in water at 37± 0.5°C using the one 
tablet (500 mg) and in the presence of artesunate tablets at 50 and 
200mg. Aliquots of 10 ml were withdrawn at 10 min interval for 60 
min and assayed. The dissolution fluid volume was maintained by 
adding 10 ml of the dissolution medium which had previously been 
maintained at 37± 0.5°C after each withdrawal. The withdrawn 
samples were assayed using UV spectrophotometer at 276 nm 
using the dissolution medium as blank. The procedure was 
repeated with four determinations, using buffer pH 1.2 at 37± 0.5°C 
as the dissolution medium.   
 
 
Antimicrobial interaction evaluation 
 
The effect of the in vitro co-presentation of artesunate and 
ciprofloxacin was evaluated on two strains each of S. aureus and E. 
coli. The bacterial strains include one clinical isolates of E. coli and 
S. aureus and their reference standards; American Type Culture 
Collection (E. coli ATCC 25922 and S. aureus ATCC 14563) 
obtained from the University College Hospital, Ibadan, Nigeria were 
used for the studies. All the bacterial cultures were grown in sterile 
nutrient broth at 37± 0.5°C for 24 h and maintained in nutrient agar 
at 4°C until use. 
 
 
Sensitivity test 
 
Overnight cultures (24 h) of E. coli and S. aureus (0.2 ml) were 
prepared by serial dilutions. Aliquots solutions (0.2 ml) of CIP 
(1.5625 × 10
-3
 – 4.0 µg/ml) was transferred into Mueller-Hinton 
broth (9 ml) followed by 0.2 ml of overnight culture of the bacterium 
and 0.6 ml of nutrient broth. The tubes were mixed and incubated 
at37°C for 24 h. The negative control contains the sterile broth, 
while the positive control contains the sterile nutrient broth, 0.8 ml 
sterile distilled water and 0.2 ml of the bacterium. The minimum 
inhibitory concentration (MIC) was defined as lowest concentration 
of the drug at which no turbidity was observed. The determination 
was done in triplicates. The procedure was also repeated with 
similar concentrations of artesunate. 
 
 
Antimicrobial assays 
 
Aliquots solutions of ciprofloxacin hydrochloride at 0.5, 1.0, 2.0  and 
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Table 1. Experimental designs for the antimicrobial drug - drug interaction 
studies between ciprofloxacin hydrochloride and artesunate. 
 
CIP (µg/ml) 
ART (µg/ml) 
0.0 0.1 0.2 0.3 
0.0 0.0/0.0 0.0/0.1 0.0/0.2 0.0/0.3 
0.5 0.5/0.0 0.5/0.1 0.5/0.2 0.5/0.3 
1.0 1.0/0.0 1.0/0.1 1.0/0.2 1.0/0.3 
2.0 2.0/0.0 2.0/0.1 2.0/0.2 2.0/0.3 
4.0 4.0/0.0 4.0/0.1 4.0/0.2 4.0/0.3 
 
CIP, Ciprofloxacin hydrochloride; ART, artesunate. 
 
 
 
4.0 µg/ml was prepared from the stock solution in buffer pH 1.2, 
while those of artesunate was similarly prepared at 0.1, 0.2, 0.3 
µg/ml from its stock solution in buffer. Diluted overnight cultures of 
the different micro organism (0.2ml) was individually introduced into 
20 ml of warm molten agar, which was carefully mixed and poured 
into sterile Petri plates and allowed to set for about 45 to 60 min. 
Wells of 8 mm were aseptically cut in the set agar in Petri plates 
inoculated with the microbial suspension. 
The pure drugs (CIP and ART) and their mixtures at the different 
combination ratios (Table 1) were prepared in test tubes which were 
covered and placed in thermostated water bath set at 37 ±0.5°C. 
Samples (0.2 ml) were carefully withdrawn from the reaction 
mixtures and transferred into the labeled wells of the seeded agar 
plates at 0, 15, 30, 45 and 60 min. The agar plates were kept for 1 
to 2 h to allow diffusion before incubation at 37 ±0.5°C for 24 h. The 
diameters of zones of inhibition were measured in mm. The 
procedure was done in triplicates and also repeated for the drug 
solutions in distilled water. 
 
 
Statistical analysis 
 
The results obtained in the research work were expressed as mean 
± standard deviation. The results were analysed using one way 
ANOVA and Student t-test (Instat 3, Statistical Package) with p< 
0.05 for level of significance. 
 
 
RESULTS AND DISCUSSION  
 
The identification and chemical content determination of 
the drug compounds authenticated the quality of the two 
drug compounds. CIP melted at 240 – 241°C with a UV 
λmax at 276 nm, while the melting point of the pure ART 
was 131 - 132°C and did not show any UV absorbance 
between 210 to 400 nm. Their chemical contents 
obtained were also within the official specification for the 
two drugs [ciprofloxacin HCl (100.8 and 98.9%w/w); 
artesunate (100.5 and 96.2%w/w) for pure drug and 
tablet dosage form, respectively] (I.P. 2003, B.P. 2010). 
The physico-chemical interaction evaluation monitored by 
using the UV spectrophotometer did not reveal any effect 
on the UV spectrum of CIP as there was no change in the 
λmax and absorbance reading at 276 nm in the presence 
of ART. This may indicate an absence of observable 
physicochemical interaction between CIP and ART. 
Dissolution of drugs is a very important step in the 
absorption of drugs from dosage forms. It is one of the 
fundamental parameters controlling the rate and extent of 
drug absorption (Gordon et al., 1995). Dissolution profiles 
of some drugs have been reportedly affected by the 
dissolution medium (Galia et al., 1998; Lobenberg et al., 
2000). Buffer pH 1.2 was used in this study to provide a 
similar medium to the normal pH of the stomach which is 
the site of drug dissolution prior to absorption. On the 
other hand, water was selected as the second medium 
because it is the specified medium for the evaluation of 
the dissolution profile of CIP (B.P. 2010). The experimen-
tal design for the dissolution profile evaluation used CIP 
tablet (500 mg), while ART at 200 mg is the starting dose 
for the management of malaria while 50 mg was used to 
observe the effect at the lower concentration of ART.  
From the results obtained, the official monographs 
specified an in vitro release of 80%w/v for CIP at 30 min; 
that is, the time to release/dissolve 80%w/v of the drug 
(T80) was 30 min. The dissolution profile of CIP in buffer 
pH 1.2 and water showed a delayed rate of release from 
the tablet dosage form in the presence of ART (Figure 1; 
Table 2). The rate of release of drugs from dosage  forms 
was obtained from the time to reach 80%w/v concen-
tration (T80). A significant increase in  T80 of CIP alone in 
buffer pH 1.2 compared with water was observed in this 
study with a T80 of 12.0 ± 4.5 and 35.3 ± 2.2 min in water 
and buffer, res-pectively (p = 0.0013). This indicates a 
significant reduction in the rate of release of CIP in buffer 
solution. However, no significant difference was observed 
in the % CIP released at 30 min (C30) in the two media in 
the absence of ART (p > 0.05). 
Furthermore, a significant increase in T80 of CIP was 
observed in the presence of 200 mg ART in both water 
and buffer solution (p < 0.05). This indicates a significant 
reduction in the rate of release/ dissolution from the tablet 
dosage form in both media. The specified in vitro 
dissolution profile of CIP tablet dosage form should be 
80%w/v at 30 min (T80 of 30 min and C30 of 80%w/v) (B.P. 
2010). A highly significant increase in T80 of CIP was ob-
served in the presence of 200 mg ART when compared 
with 50 mg in both media (p < 0.05). Moreover, the CIP 
release in the presence of 200 mg ART at 30 min was 
lower than specified 80%w/v in both media (Table 2), 
while the time to  achieve  80%w/v  dissolution  was  also 
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Table 2. Dissolution profiles (T80 and C30) of ciprofloxacin hydrochloride tablet in the presence of artesunate tablets at 50 and 200 mg (mean ± S.D.). 
 
Sample 
T80 (% ± S.D.)  C30 (min ± S.D.) 
Buffer pH 1.2 Water  Buffer pH 1.2 Water 
CIP alone 35.3 ± 2.2 12.0 ± 4.5  73.3 ± 1.3 89.8 ± 14.8 
CIP + 50 mg ART 25.6 ± 11.9 13.7 ± 8.4  83.9 ± 10.9 97.9 ± 7.5 
CIP + 200 mg ART 53.5 ± 7.6 46.5 ± 0.9  21.7 ± 6.9 65.9 ± 6.1 
p value (ANOVA) 0.0164 0.0029  0.0001 0.0565 
 
CIP, Ciprofloxacin hydrochloride; ART, artesunate. 
 
 
Table 3. Zones of inhibition (mm) of ciprofloxacin hydrochloride (CIP) (0 – 4ug/ml) in the presence of artesunate (ART) (0.1 – 0.3ug/ml) at 0 and 60minutes against two strains of S. 
aureus and E. coli.    
 
Organism 
ART concentration 
(ug/ml) 
Zone of inhibition at different concentrations of CIP (ug/ml) at 0 and 60 min (mm) 
0.5  1.0  2.0  4.0 
0 60  0 60  0 60  0 60 
SAT 
0.1 15.7 ± 3.21 17.7 ± 1.15  22.3 ± 3.51 22.0 ± 0.1  23.3 ± 2.1 23.5 ± 2.0  24.7 ± 2.1 23.5 ± 0.7 
0.2 20.0 ± 2.82 16.3 ± 7.23  18.7 ± 3.2 20.3 ± 3.5  22 ± 1.0 22.5 ± 3.5  26.3 ± 1.5 24.0 ± 2.7 
0.3 18.3 ± 2.08 22.3 ± 2.31  18.3 ± 7.0 26.7 ± 0.6  21.7 ± 1.2 21.0 ± 1.0  24.7 ± 0.6 24.7 ± 2.9 
             
SAC 
0.1 17.3 ± 3.0 16.3 ± 3.1  22.7 ± 4.7 20.3 ± 1.5  22.7 ± 4.0 17.7 ± 5.7  28.0 ± 2.0 23.7 ± 3.8 
0.2 20.7 ± 0.6 11.3 ± 1.5  21.3 ± 4.2 12.0 ± 5.0  20.3 ± 0.6 21.0 ± 1.0  28.0 ± 3.6 22.7 ± 0.6 
0.3 19.7 ± 4.5 16.7 ± 1.5  24.0 ± 1.7 18.3 ± 2.5  22.7 ±2.5 21.0 ± 1.0  27.7 ± 2.1 23.3 ± 1.5 
             
ECT 
0.1 24.3 ± 1.5 25.7 ± 5.5  28.3 ± 1.5 22.3 ± 1.2  30.7 ± 0.6 29.7 ± 1.5  31.0 ± 3.5 32.0 ± 1.0 
0.2 24.7 ±1.5 20.7 ± 2.1  30.7 ± 4.0 28.7 ± 4.9  30.7 ± 1.2 26.3 ± 7.7  26.0 ± 4.4 30.7 ± 1.5 
0.3 24.3 ± 3.2 22.0 ± 5.1  32.3 ± 4.1 27.3 ± 4.6  31.7 ± 1.5 26.7 ± 1.5  31.0 ± 2.7 33.0 ± 1.0 
             
ECC 
0.1 26.0 ± 4.0 27.3 ± 2.3  33.7 ± 2.9 30.0 ± 2.5  32.0 ± 1.0 27.7 ± 0.6  34.7 ± 0.6 33.3 ± 0.6 
0.2 33.3 ± 3.2 25.0 ± 3.0  30.7 ± 1.2 28.7 ± 2.5  33.7 ± 2.9 28.7 ± 1.2  36.7 ± 0.6 28.0 ± 1.7 
0.3 32.7 ± 2.5 22.0 ± 1.0  31.7 ± 2.5 31.0 ± 1.7  30.7 ± 1.2 26.7 ± 2.1  37.0 ± 1.0 31.3 ± 3.1 
 
 
higher than the 30 min in the presence 200 mg 
ART.  The increased T80 and decreased C30 with 
ART at 200mg imply an increase in the time to 
achieve appreciable biological concentration as a 
result of delayed rate of in vivo drug absorption. 
This may cause a decrease in the rate of achie-
ving desired therapeutic effect, which may result 
in a compromise of the  therapeutic  outcome.  On  
the other hand, the significant difference in the 
dissolution profile of CIP alone in buffer pH 1.2 
and water is an indication that the use of water to 
define the dissolution profile may not be a good 
indicator of the dissolution profile of CIP in 
biological medium. 
In addition, the microbial sensitivity test showed 
that the micro organisms used in  this  study  were  
sensitive to the CIP at 0.25 to 4.0 µg/ml, while 
ART expectedly did not show any antimicrobial 
activity even at the highest concentration of 0.4 
µg/ml. The effect of ART on in vitro antimicrobial 
effect of CIP on E. coli and S. aureus revealed a 
decrease in the antimicrobial activity on the 
clinical isolates which were however found to be 
statistically   insignificant    (p  >  0.05)    (Table 3).  
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Figure 1. Dissolution profile of ciprofloxacin hydrochloride tablet (500 mg) in the presence of artesunate 
tablet at 50 and 200 mg in water and buffer pH 1.2 at 37± 0.5°C (CIP: ciprofloxacin hydrochloride; ART: 
artesunate). 
 
 
 
Nevertheless, no difference in antimicrobial activity was 
observed with the reference micro organisms (SAT and 
ECT) across the different concentrations used in this 
study. 
 
 
Conclusion  
 
Although no significant difference was obtained with the 
physico-chemical interaction study, the alteration in the 
dissolution profile of CIP in the presence of 200 mg ART 
calls for caution during the administration of CIP with 
starting dose of ART. This is further important in view of 
the obtained result of non-statistically significant 
reduction in antimicrobial activity obtained with the clinical 
isolates. It is hereby suggested that care should be taken 
during the co-administration of CIP with the starting dose 
of ART. An adequate time interval should be observed in 
order to avoid compromising the therapeutic outcome.  
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The aim of the present study was to characterize comparative excretion of pure vitexin-2"-O-rhamnoside 
(VR) in mice following oral and intravenous administration at dose of 30 mg/kg, therefore, a sensitive 
and specific high-performance liquid chromatography (HPLC) method using vitexin-4"-O-glucoside as 
internal standard developed and validated for quantitative analysis of VR. The results of elimination of 
VR in urinary and fecal excretion following oral and intravenous dosing indicated that VR was mainly 
excreted as prototype for both routes of administration, and biliary and renal excretions are two major 
ways of elimination of VR. 
 
Key words: Excretion, high-performance liquid chromatography (HPLC), Vitexin-2"-O-rhamnoside.  
 
 
INTRODUCTION 
 
Vitexin-2"-O-rhamnoside (VR) abundantly exists in fruits 
and leaves of Crataegus pinnatifida Beg. var major 
(hawthorn and hawthorn leaves), both of which are very 
popular herbal materials in traditional Chinese medicine 
(TCM) and are well used in treating cardiovascular 
diseases (PRC, 2010). As VR is one of the main 
components of flavonoid of hawthorn leaves (Ding et al., 
1990) and also a bioactive constituent on cardiovascular 
system in hawthorn (Liang et al., 2007), many pharma-
cological studies of VR have been reported until now, 
such as protective effect on the injured cardiac myocytes 
and endothelial cells (Zhu et al., 2003, 2006) and strongly 
inhibiting deoxyribonucleic acid (DNA) synthesis in MCF-
7 human breast cancer cells (Ninfali et al., 2007). In 
recent years, many articles focus on in vitro study and 
pharmacokinetic studies (Cheng et al., 2007; Ying et al., 
2007, Du et al., 2011). However, there is little research on 
the comparative excretion of pure VR isolated from 
hawthorn leaves following oral and intravenous  routes  of 
administration. In our study, a sensitive and specific high-
performance liquid chromatography (HPLC) method 
using vitexin-4"-O-glucoside (VG) as internal standard 
thereby was first established to fully evaluate the urinary 
and fecal excretion content of VR following oral and 
intravenous route of administration. In addition, the 
differences of excretion after two forms of administration 
can be identified. 
 
 
MATERIALS AND METHODS 
 
Reagents and chemicals 
 
The water used in all experiments was purified by a Milli-Q
®
 Biocel 
Ultrapure Water System (Millipore, Bedford, MA, USA). Methanol, 
acetonitrile and tetrahydrofuran were all of HPLC grade and 
purchased from Xinxing Chemical Reagent Plant (Shanghai, 
China). All other chemicals of analytical grade were obtained from 
Sinopharm Chemical Reagent Co., Ltd (Shanghai, China). 
 
*Corresponding author. E-mail: yingxixiang@163.com. 
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Figure 1. (A) Chemical structure of vitexin-2"-O-rhamnoside. (B) Chemical structure of 
vitexin-4"-O-glucoside (I.S.). 
 
 
 
Plant  
 
Leaves of C. pinnatifida Bge.var major were collected in Shenyang, 
Liaoning Province, China and identified by Prof. Ting-Guo Kang. A 
voucher specimen (20110921) was deposited in Liaoning University 
of Traditional Chinese Medicine. 
 
 
Extraction and isolation 
 
A sample of the leaves (2 kg) of C. pinnatifida Bge. var. major was 
cut in small pieces and refluxed with 60% aqueous ethanol for two 
times, each for 2 h. The crude extract after concentrated under 
reduced pressure was then adsorbed on a porous-polymer resin 
(AB-8, Tianjin, China) column, removed impurity with water and 
eluted with a gradient of 30, 50 and 70% ethanol. The fraction 
eluted with 30% ethanol was evaporated under reduced pressure to 
obtain extract, which was then chromatographed on silica gel 
column and eluted with ethyl acetate/butanone/formic acid/water 
3:3:1:1. Fractions of similar composition were pooled on the basis 
of TLC analysis (UV monitoring at 365 nm) were repeatedly 
subjected to silica gel column chromatography and eluted with ethyl 
acetate/butanone/formic acid/water 5:3:1:1 to directly obtain crystal 
of VR (1 g) and VG (0.2 g) internal standard (I.S.), and purities of 
them were both over 99% by HPLC analysis. The chemical 
structures of VR and VG, confirmed by 
1
HNMR, 
13
CNMR and MS 
data, are shown in Figure 1. 
 
 
Chromatographic system 
 
The analysis was carried out on an Agilent 1100 series HPLC 
system (Agilent technology, Palo Alto, CA, USA) which consisted of 
a quaternary Pump (G1310A), a vacuum degasser (G1322A), a 
UV-VIS spectrophotometric detector (G1314A) and Chemstation 
software (Agilent). The analytical column was a Diamonsil C18 
column (150 mm × 4.6 mm i.d., 5 μm, Diamonsil, USA) protected by 
a KR C18 guard column (35 mm × 8.0 mm, i.d., 5 μm, Dalian 
Create Science and Technology Co., Ltd., China). The optimal 
mobile phase used for separation is a mixture consisting of 
methanol-acetonitrile-tetrahydrofuran-1%    glacial       acetic     acid  
(6:2:18:74, v/v/v/v). All the chromatographic measurements were 
performed at room temperature and a flow rate of 1 ml/min with the 
detection wavelength of 330 nm. 
 
 
Preparation of standards and quality control samples 
 
Standard stock solutions of VR and I.S. were both prepared in 
methanol to yield the concentrations of 4000 μg/ml and 276 μg/ml, 
respectively. Stock solution of VR was serially diluted with methanol 
to desired concentrations over the range of 0.16 to 3200 μg/ml. All 
the solutions were stored at 4°C before use. The calibration 
samples were prepared by spiking 200 μl blank mouse urine or 500 
μl blank feces homogenates successively with appropriate amount 
of working solutions of VR (50 μl), acetic acid (20 μl) and I.S.. The 
volume of I.S. is 40 μl for urine samples and 80 μl for feces sam-
ples. The quality control samples of VR in the method validation 
were similarly prepared to the standard calibration samples. 
 
 
Animals and dosing 
 
SPF male Kunming strain mice (20 ± 2 g) were obtained from the 
Experimental Animal Center of Liaoning University of Traditional 
Chinese Medicine (Shenyang, China) and housed in an air-
controlled breeding room for a week. Before starting the 
experiment, all the mice formerly free access to standard laboratory 
food as well as water ad libitum were fasted for more than 12 h. All 
experiments involving animals were approved by the animal ethics 
committee of Liaoning University of traditional Chinese medicine 
and performed according to the Guidelines for Animal 
Experimentation of this institution. For excretion studies, ten mice 
were randomly divided into two groups to be administrated VR at 
dose of 30 mg/kg. Among the two groups, one was orally 
administrated and the other intravenously administrated. All the 
mice were respectively housed in stainless-steel metabolism cages 
to collect urine and feces at different time. Two hours after 
administration, water and standard laboratory food were offered. 
Urine and feces samples were collected at 0 to 2, 2 to 4, 4 to 6, 6 to 
8, 8 to 12 and 12 to 24 h post-dosing. The volume of each collected 
urine sample and the weight of each collected feces sample were 
separately recorded.  All  the  sample s were  stored  at -20°C  until 
analysis.
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Figure 2. Typical chromatograms of urine excretion study (A-D) respectively obtained from blank urine 
sample, blank urine sample spiked with standard analyte and I.S., and urine samples collected from 4 to 
6 h following oral and intravenous routes of administration of VR at dose of 30 mg/kg. 
 
 
 
Sample processing 
 
To 200 μl urine samples, 20 μl of acetic acid, 40 μl of I.S. and 1 ml 
of methanol were successively pipetted, followed by vortex mixing 
for 1 min. After samples being centrifuged at 890 g for 15 min, the 
supernatant was separated and evaporated to dryness under a 
gentle stream of nitrogen at 50ºC. The residue was diluted in 200 μl 
of mobile phase and again centrifuged at 15,092 g for 10 min. Then 
an aliquot (20 μl) of clean supernatant was injected into HPLC 
column for analysis. Feces (0.2 g) were homogenized in 0.5 ml of 
saline solution. The homogenate was successively added 20 μl of 
acetic acid, 80 μl of I.S. and 2 ml of methanol  and  then  treated  as 
urine samples. 
RESULTS AND DISCUSSION 
 
HPLC chromatograms 
 
Typical chromatograms of urinary and fecal excretion 
studies are shown in Figures 2 and 3, respectively. The 
total run time was no more than 20 min and the retention 
times of I.S. and VR were approximately 6.6 and 8.7 min, 
with no interfering peaks detected at the retention times 
of VR or I.S. 
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Figure 3. Typical chromatograms of fecal excretion study (A-D) respectively obtained from blank feces 
sample, blank feces sample spiked with standard analyte and I.S., and feces samples collected from 6 
to 8 h following oral and intravenous routes of administration of VR at dose of 30 mg/kg. 
 
 
 
Method validation 
 
Method validation involves linearity, precision, limit of de-
tection (LOD), limit of quantification (LOQ), recovery and 
stability. The linear range for urine and feces were within 
0.4 to 400 μg/ml with R
2
 > 0.99. The LOD (S/N > 3) and 
the LOQ (S/N > 10) were respectively 0.121 and 0.363 μg/ml 
in urine and 0.121 and 0.363 μg/g in feces. Both of the 
precision (RSD%) and accuracy (RE%) were below 15%, 
conforming to the criteria for the analysis of biological 
sample according to guidance of USFDA. The  extraction  
recoveries of VR in urine and feces ranged from 82.36 ± 
5.82% to 108.9 ± 8.47%. The results of short-term stabi-
lity, long-term stability and freeze-thaw stability indicated 
that no remarkable degradation occurred during chro-
matography, extraction and sample storage processes for 
excreta samples.  
 
 
Excretion studies 
 
Figure 4 shows the urinary and fecal excretion time profiles 
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Figure 4. (A) Urinary cumulative ratio of vitexin-2"-O-rhamnoside in mice (mean ± S.D., n = 5) following oral and intravenous routes of 
administration at dose of 30 mg/kg. (B) Fecal cumulative ratio of vitexin-2"-O-rhamnoside in mice (mean ± S.D., n = 5) following oral and 
intravenous routes of administration at dose of 30 mg/kg. 
 
 
 
of VR following oral and intravenous administration at 
dose 30 mg/kg. The urinary and fecal cumulative ratios of 
unchanged VR amounted to 4.13 ± 0.01% and 38.89 ± 
3.04% after oral administration, and amounted to 12.83 ± 
0.03% and 24.65 ± 1.75% after intravenous administra-
tion. VR as prototype was detected in excreta by com-
paring HPLC chromatogram of blank biological samples 
with the tested one. The total VR recoveries of excreta 
were 37.48 ± 1.78% (12.83 ± 0.03% in urine; 24.65 ± 
1.75% in feces) following intravenous dosing and 43.02 ± 
3.05% (4.13 ± 0.01% in urine; 38.89 ± 3.04% in feces) 
following oral dosing, demonstrating that biliary excretion 
and renal excretion are two major ways of elimination of 
VR and VR underwent extensive first-pass effect after 
oral administration and that not being absorbed was 
mainly excreted as feces. Recently, Ma et al. (2010) 
studied the excretions of VR after orally administrated 
hawthorn leaves extract and found that the total recovery 
of the dose in 24 h was 89.01% (0.72% in urine; 88.29% 
in feces) for VR (Ma et al., 2010), which is different from 
the results of monomer administration of VR were 43.02 
± 3.05% (4.13 ± 0.01% in urinary excretion; 38.89 ± 
3.04% in fecal excretion) following oral dosing, 
suggesting that various kinds of components in hawthorn 
leaves extract affect the concentration and duration of VR 
in vivo. 
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Preparation of sustained release dosage forms is one of the main objectives in drug formulation. 
Tramadol is a centrally acting synthetic opioid analgesic used in treating severe pain. In this study, 
Tramadol sustained release pellets were prepared using two methods and the effect of type, ratio of 
polymers and plasticizers on drug loading and drug release profile was studied. From the results 
obtained, it seems that Eudragit RL is not a suitable choice and when Tween was used as plasticizer. 
Moreover, when mixture of Eudragit S and RS were applied as polymers, the optimum drug release 
profile was obtained and after 10 h, 95% of loaded drug was released. 
 
Key words: Eudragit, Tramadol, sustained release, plasticizer, pellet. 
 
 
INTRODUCTION 
 
Multi-particulate drug delivery systems are mainly oral 
dosage forms consisting of a multiplicity of small discrete 
units, each exhibiting some desired characteristics. In 
these systems, the dosage of the drug substances is 
divided on a plurality of subunit typically consisting of 
thousands of spherical particles with diameter of 0.05 to 
2.00 mm. Thus multi-particulate dosage forms are phar-
maceutical formulations in which the active substance is 
present as a number of small independent subunits (Dey 
et al., 2008). Multiparticulate systems show better 
reproducible pharmacokinetic behavior than conventional 
(monolithic) formulations. Some other studies were done 
to   investigate   pharmacokinetics   of  sustained  release 
dosage forms prepared using ion exchange resins (Liu et 
al., 2012). Drug safety may also be increased by using 
multiparticulate dosage forms, particularly for modified 
release systems (Laila and Chandran, 2006; Hu et al., 
2006). 
Multiparticulates may be prepared by several methods. 
Some of these methods may be broadly classified as 
pelletization, granulation, spray drying, and spray 
congealing (Bechegaard and Nielson, 1978). Pelletized 
delivery system (PDS) is a sustained release system 
using pellets or beads manufactured using 
marumerization/ spheronization/ pelletization techniques, 
or by layering powders or  solutions  on  nonpareil  seeds 
*Corresponding author. E-mail: ghafari@pharm.mui.ac.ir or soligh@yahoo.com. Tel: +98 21 88275524, +989125272146. 
Fax: +98 21 55543301.  
  
 
 
(Dey et al., 2008; Hu et al., 2006) and controlled drug 
release systems can be assembled from either polymers 
or pumps. Because of their small size and lower cost, 
polymers are most widely employed (Garala et al., 2009). 
Pelletization is a technique that enables the formation of 
spherical beads or pellets. These pellets can eventually 
be coated and very often used in controlled-release 
dosage forms (Hirjau et al., 2011). 
Pelletization methods used in the pharmaceutical 
industry can be grouped by various criteria, e.g. by the 
type of equipment used, the intensity of the mechanical 
forces involved or the techniques employed for the 
production of pellets. The success of these methods de-
pends on the complex relations between the equipment, 
the formulation and process variables (Hirjau et al., 2011; 
Bechegaard and Nielson, 1978). Different pelletization 
methods are as follows: 
 
(a) Extrusion / spheronization (Liew et al., 2000; Ghai et 
al., 2009; Zhang et al., 2012). 
(b) Fluid-bed Granulation. 
(c) Rotogranulation is one of the most recent methods for 
the production of spheroids. 
(d) Layering a suspension or a solution of a drug on a 
seed material. 
(e) Dry powder layering is some method in which process 
is similar to the solution or suspension layering. 
(f) Spray-drying represents another process. 
(g) Spray-congealing (spray-chilling) is a technique 
similar to spray-drying (Schaefer and Kristensen, 1993; 
Bechegaard and Nielson, 1978; Haritha, 2012). 
 
Tramadol hydrochloride is a centrally acting synthetic 
opioid analgesic used in treating severe pain. The drug 
has a wide range of applications, including treatment for 
rheumatoid arthritis, restless legs syndrome and fibro-
myalgia. Tramadol comes in many forms, including 
capsules, tablets, suppositories, effervescent tablets, 
powders, and ampoules for subcutaneous injection (SC), 
intra-muscular injection (IM), and intravenous (IV) 
injection and liquids (Trease, 1964). In this study, sus-
tained release pellets of Tramadol were prepared using 
two different methods and in addition to comparing the 
suitability of designed methods, the effect of type of 
polymers, ratio of polymer to drug as an important factor 
which was studied in other sustained release formu-
lations (Jan et al., 2012), type of emulsifiers, amount of 
used emulsifiers and core particle size on drug loading 
and drug release profile were studied. 
 
 
MATERIALS AND METHODS 
 
Tramadol hydrochloride (Figure 1) was purchased from Palace, 
Italy. Eudragit RS100, S, L and RL were purchased from Rohm 
Pharma, Germany. Sucrose, polyvinylpyrrolidone (PVP), 
isopropanol, acetone, ethanol, polyethylene glycol 400 (PEG 400), 
Tween 20 and 40, potassium hydrogen phosphate, sodium 
hydroxide, talc, titanium dioxide and acid  chloride  were  purchased 
from Merck, Germany. 
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Preparation of pellets 
 
For preparation of pellets in this study, two different methods were 
applied. In the first method, primary cores were designed using 
sieved sucrose and the addition of PVP suspension in isopropyl 
alcohol, and then the suspension of other components including: 
calcium carbonate, talc, titanium dioxide and corn starch in water. 
The prepared cores were separated by sieving method using a 
sieving machine (Teb Azma, Iran), after which loading of drug was 
done on the cores and finally polymers were used to coat designed 
drug loaded pellets. This method was designed to prepare spherical 
core with high ratio of surface to volume and to increase probability 
of more drug loading efficiency on them. For this approach, sucrose 
was sieved using sieves with 16 - 50 mesh size and the fraction of 
sucrose that remained on sieve with 40 mesh size was chosen to 
be as core. Table 1 shows the US standard for relation of mesh 
size and particle size that was applied in this study. From the table, 
sucrose was 420 micron in size. Three different formulations for first 
layer were designed and added to sucrose to reach more spherical 
cores in shape and to protect sucrose as a core. Tables 2 to 5 show 
different suspension of the first layer on sucrose. For loading of 
drug on the designed cores, mixture of drug and excipients was 
sprayed on cores using hand spray gun and coating pan (Erweka, 
Germany) in different steps to load enough drug. Although some 
other studies investigated the effect of different experimental 
parameters on characterization of microcapsules (Esposito et al., 
2000), in this study experimental parameters fixed and the effect of 
presented parameters like ratio and type of polymers and solvents 
were studied. Tables 6 to 9 show the drug and different polymers in 
different ratio mixture that were sprayed on the cores to prepare 
controlled release pellets. 
In second method for the preparation of cores, mixture of drug 
and excipients were used instead of sucrose, using pelletiser 
(Pelletiser GTE, Erweka, Germany) and then polymers were added 
to the surface of desired pellets. For preparation of pellets based on 
the second method, first mixture of drug and some excipients were 
poured into the pelletiser to make primary cores as it is shown in 
Table 10. As for the first layer, solution of PVP (10%) in ethanol was 
sprayed on the desired cores to help powders to adhere to each 
other and make cores. The second layer was formulated as 
described in Table 11 and sprayed to the surface of the cores. 
Desired cores were sieved with sieve sizes of 16 - 40. The cores 
remaining on the sieve size 20 and 25 were selected and mixed to 
continue the study. Also, cores remaining on sieve size 18 were 
separately collected for further studies. Then formulations as 
described in Tables 12 and 13 were prepared to spray on selected 
cores. Finally, analyses of desired pellets were done. 
 
 
Determination of λ max of Tramadol 
 
Absorbance of serial dilution of Tramadol in water and phosphate 
buffer solution (PBS) pH: 6.8 were studied to determine λ max of 
Tramadol. 
 
 
Drug loading efficiency 
 
Briefly, 100 mg of cores and 100 mg pellets containing drug were 
weighed separately, extruded and dissolved in 100 ml purified 
water. Pure cores solution was used as blank and Tramadol assay 
was done in detected λ max. 
 
 
Drug release study 
 
Dissolution test was done at a desired condition as follows: medium 
of dissolution was 500 ml water, apparatus  number  І, 100  RPM  at 
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Table 1. US standard for relation between 
mesh size of sieves and particle size of 
materials. 
 
US standard 
Mesh size  Particle size (µ) 
10 2000 
12 1680 
14 1410 
16 1190 
18 1000 
20 840 
25 710 
30 590 
35 500 
40 420 
45 350 
50 97 
 
 
 
Table 2. Component of formulation 1 that applied 
as first layer on sucrose core in the first method. 
 
Material Percentage (%) 
Sucrose 50 
Talk 10 
Calcium carbonate 10 
PVP 1 
Titanium dioxide 0.5 
Water Up to 100 
 
 
Table 3. Component of formulation 2 that 
applied as first layer on sucrose core in the first 
method. 
 
Material Amount (g) 
Sucrose 35 
Calcium carbonate 30 
Talk 5 
PVP 1 
Titanium dioxide 0.5 
Corn starch 10 
water 30 
 
 
37.5±0.5°C. The sampling interval was 1 h, in each interval 5 ml 
samples was gathered and fresh medium was replace. The medium 
of dissolution for pellets containing Eudragit S and L was changed 
to HCL 0.1 N for the first 2 h and then PBS, pH:6.8 because these 
Eudragits are pH sensitive. 
 
 
RESULTS AND DISCUSSION 
 
Calibration curve of tramadol in water and PBS 
 
The λ max  of  272 nm  was  selected  for  Tramadol  and  
 
 
 
 
Table 4. Component of formulation 3 that 
applied as first layer on sucrose core in the 
first method. 
 
Material Amount (g) 
Sucrose 35 
Calcium carbonate 30 
Talk 8 
PVP 1 
Titanium dioxide 0.5 
Corn starch 10 
Water 35 
Ethanol 5-10% 
 
 
 
Table 5. Components of tramadol containing 
solution which was sprayed on the cores in 
firs pellet preparation method. 
 
Material Amount 
Tramadol HCL 5 (g) 
Eudragit RS100 5(g) 
TEC 15% 
Ane 50 (ml) 
Ethanol 50 (ml) 
 
 
 
calibration curve was designed as shown in Figure 2. The 
R2 of the both curves was 0.999. 
 
 
Drug loading on pellets 
 
The amount of drug loaded on the desired pellets is 
shown in Table 14. According to the results, formulations 
F1, 5, 7, 8, 10 and 11, F13 to 16 and also F19-21 and 24 
had drug loading more than 11%. 
 
 
Drug release 
 
Figure 3 shows drug release profile of pellets that was 
studied in water medium. As shown, formulation number 
5, 7 and 9 had a significant burst effect and more than 
50% of loaded drug was released through them in the 
first hour. In formulation F8, at the first sampling time, 
81% of loaded drug was released and no significant 
change was observed in 8 h (data not shown). Study of 
drug release profile through desired pellets showed that 
usage of polymeric mixture with concentration of 90% 
Eudragit RS and 10% Eudragit S could be suitable 
formulation to design sustained release pellets. Usage of 
total electron content (TEC) and Tween 40 in ratio of 20 
to 5%, respectively in coating solution could cause the 
preparation of pellets with spherical shape, reasonable 
drug loading and sustained drug release profile. Figures 
3 to 5 show the drug release profile; comparison  of  F1 –  
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Table 6. Formulations of pellets which containing Eudragit RS. 
 
Formulation 
number 
Ratio of polymer 
to drug 
Acetone 
(ml) 
Ethanol 
(ml) 
Tween 20 
(g) 
PEG 
400 
TEC 
(g) 
Eudragit RS 
(g) 
F1 0.25 50 50 - - 0.75 5 
F2 0.27 50 50 - - 0.75 5 
F3 0.39 50 50 - - 0.75 5 
F4 0.88 50 50 - - 0.75 5 
F5 0.25 50 50 - 0.75 - 5 
F6 0.30 50 50 - 0.75 - 5 
F7 0.20 50 50 0.75 - - 5 
F8 0.26 50 50 0.75 - - 5 
F9 0.31 50 50 0.75 - - 5 
 
 
Table 7. Formulations of pellets which containing Eudragit RS and S. 
 
Formulation 
number 
Ratio of polymer 
to drug 
Acetone 
(ml) 
Ethanol 
(ml) 
Tween 20 
(g) 
TEC 
(g) 
Eudragit S 
(g) 
Eudragit RS 
(g) 
F10 0.3 50 50 - 0.75 0.5 4.5 
F11 0.35 50 50 - 0.75 0.5 4.5 
F12 0.45 50 50 - 0.75 0.5 4.5 
F13 0.20 50 50 0.25 1 0.5 4.5 
F14 0.31 50 50 0.25 1 0.5 4.5 
F15 0.36 50 50 0.25 1 0.5 4.5 
F16 0.44 50 50 0.25 1 0.5 4.5 
F17 0.70 50 50 0.25 1 0.5 4.5 
F18 0.76 50 50 0.25 1 0.5 4.5 
 
 
Table 8. Formulations of pellets which containing Eudragit RS and L. 
 
Formulation number Ratio of polymer to drug Acetone (ml) Ethanol (ml) TEC (g) Eudragit L(g) Eudragit RS (g) 
F19 0.36 50 50 0.75 0.5 4.5 
F20 0.40 50 50 0.75 0.5 4.5 
F21 0.45 50 50 0.75 0.5 4.5 
F22 0.47 50 50 0.75 0.5 4.5 
F23 0.55 50 50 0.75 0.5 4.5 
 
 
Table 9. Formulations of pellets which containing Eudragit RL. 
 
Formulation number Ratio of polymer to drug Acetone (ml) Ethanol (ml) TEC (g) Eudragit RL (g) 
F24 0.28 50 50 0.75 10 
F25 0.31 50 50 0.75 10 
F26 0.42 50 50 0.75 10 
F27 0.51 50 50 0.75 10 
 
 
Table 10. Materials which used to prepare 
primary cores based on second method. 
 
Material Amount (g) 
Tramadol HCL 10 
Lactose  20 
Corn starch 20 
PVP 2.5 
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Table 11. Materials which used as second layer to 
prepare pellets based on second method. 
 
Material Amount (g) 
Sucrose 25 
Calcium carbonate 30 
Talk 8 
PVP 2 
Titanium dioxide 0.5 
Corn starch 15 
Water 30 
Ethanol 30 
 
 
 
Table 12. Materials used to spray on cores of second method with size of 710-840 µ. 
 
Formulation 
no  
Eudragit RS 
(g) 
Eudragit S 
(g) 
TEC 
(g) 
Tween 40 
(g) 
Ethanol 
(ml) 
Acetone 
(ml) 
Ratio of polymer 
to drug 
F′13 4.5 0.5 1 0.25 50 50 0.20 
F′14 4.5 0.5 1 0.25 50 50 0.30 
F′15 4.5 0.5 1 0.25 50 50 0.36 
F′16 4.5 0.5 1 0.25 50 50 0.45 
F′17 4.5 0.5 1 0.25 50 50 0.70 
 
 
 
Table 13. Materials used to spray on cores of second method with size of 1000 µ. 
 
Formulation 
no 
Eudragit RS 
(g) 
Eudragit S 
(g) 
TEC 
(g) 
Tween 40 
(g) 
Ethanol 
(ml) 
Acetone 
(ml) 
Ratio of polymer 
to drug 
F"14 4.5 0.5 1 0.25 50 50 0.30 
F"15 4.5 0.5 1 0.25 50 50 0.35 
F"16 4.5 0.5 1 0.25 50 50 0.44 
F"17 4.5 0.5 1 0.25 50 50 0.70 
F"18 4.5 0.5 1 0.25 50 50 0.75 
 
 
 
Table 14. Results of drug loading on pellets. 
 
Formulation no. Amount of drug (mg %) 
F1 11.06 ± 0.079 
F2 10.91 ± 0.089 
F3 9.47 ± 0.369 
F4 8.21 ± 0.373 
F5 11.06 ± 0.195 
F6 10.74 ± 0.130 
F7 11.39 ± 0.284 
F8 11.01 ± 0.079 
F9 10.47 ± 0.065 
F10 12.13 ± 0.073 
F11 11.56 ± 0.186 
F12 10.97 ± 0.146 
F13 12.62 ± 0.075 
 
Table 14. Contd. 
 
F14 12.06 ± 0.107 
F15 11.48 ± 0.132 
F16 11.1 ± 0.064 
F17 8.89 ± 0.2407 
F18 7.89 ± 0.140 
F19 12.32 ± 0.167 
F20 11.95 ± 0.188 
F21 11.63 ± 0.193 
F22 10.98 ± 0.293 
F23 10.64 ± 0.603 
F24 11.25 ± 0.117 
F25 10.82 ± 0.172 
F26 10.52 ± 0.186 
F27 10.14 ± 0.235 
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Figure 1. Chemical structure of Tramadol HCL. 
 
 
 
F4 shows that in these formulations, increasing the ratio 
of polymer reduces the amount of drug release, es-
pecially at first release times. Comparison of F1, F5 and 
F8 shows that different plasticizers may cause different 
drug release profile; all parameters were equal in these 
formulations and just the type of plasticizer was changed. 
The desired changes showed that TEC with hydrophobic 
character could be responsible for less drug release in 
formulation F1 versus Tween with hydrophilic character, 
which used in F8 and led to more drug release. 
Furthermore, in F5 with PEG as a plasticizer, release 
profile shows intermediate condition in comparison with 
F1 and F8. Comparison of F2, F6 and F9 shows the 
same results. TEC was selected as a better plasticizer to 
achieve pellets with steady release condition and no sig-
nificant burst effect. Regarding the drug release results, it 
seems that Eudragit RS and Tween in legal ratio of poly-
mer usage could not help to design controlled release 
formulation and most of the drug was released at the first 
sampling times. 
Study on drug release profile of F10 - 12 in which just 
ratio of polymer was increased, shows that increasing po-
lymer could sustain the release profile and when mixture 
of Eudragit RS and S was used; results were more 
reasonable. A study of F19 - 23 shows that formulations   
which   were   prepared   using   mixture of Eudragit RS 
and L were not suitable to prepare pellets with predicted 
drug release profile. Based on F24 – 27 we estimated 
that usage of Eudragit RL could cause higher range of 
drug release at initial sampling point. Comparison of 
Eudragit RS with RL shows that ammonium groups in 
Eudragit RL are more than RS and this reason causes 
more solubility of Eudragit RL in equal ratio. The for-
mulation containing Eudragit RS could retain the release 
of drug more than Eudragit RL. These two types of 
Eudragit are not pH dependent. In comparison of 
Eudragit S and L, Eudragit S could release drug in pH 
ranges more than 7 and this range for Eudragit L is more 
than 6. Hence, Eudragit S could be use as polymer for 
colon drug delivery and the drug release through it is 
more sustained. To compare the effect polymer type on 
drug release profile, formulations F3, 11, 20 and 26 were 
studied in which the amount of polymers was 0.4 and 
formulations contained Eudragit RS, mixture of RS and S, 
RS and RL, respectively. Results showed that more 
water permeability and more solubility of Eudragit RL 
does not mean that it will be a suitable polymer for sus-
tained drug release. The sustainability of these Eudragit 
was in the condition as shown: Mixture of S and RS > RS 
> mixture of RS and RL > RL. Therefore, the study was 
continued using mixture of Eudragits S and RS. 
In addition, based on the results of plasticizers which 
were used (TEC, PEG 400 and Tween), TEC as an 
insoluble plasticizer could cause more sustained 
formulations. More studies showed that the best condition 
to achieve formulation with desired drug release profile 
will be when the mixture of Eudragit S and RS in of ratio 
of 90, 10 and the mixture TEC and Tween in ratio of 20, 5 
were applied. Formulations F13 - 16 had such a 
condition. In comparison, F16 showed more reasonable 
drug release profile and drug release profile was studied 
for 10 h on it; Figures 6 and 7 shows the result. Studies 
showed that the kinetic of drug release through 
formulation F16 matched with zero order. The R2 of zero, 
first and Higushi kinetic was 0.963, 0.910 and 0.955, 
respectively. 
Previous studies have been done to evaluate the ratio 
of different kinds of Eudragits on the in vitro release 
profile of drug (Hu et al., 2006; Bidah and Vergnaud, 
1991; Golman and Jalilpak, 2008; Yadav and Jain, 2011; 
Adibkia et al., 2012). Some studies showed that the 
combination of two different acrylic polymers showed 
better effect on the release kinetics of drug than any 
individual polymer coated pellets to sustain the release of  
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Figure 2. Calibration curve of Tramadol in water in λ max:272 nm. 
 
 
 
 
 
Figure 3. Drug release profile through formulation F1 - F9 in water medium. 
 
 
 
drug over a period of time, with better dissolution profile 
as well as better linearity in drug (ketoprofen) release 
kinetics (Golman and Jalilpak, 2008). Some other studies 
showed that when Eudragites were used in formulation, 
results were affected by the type and ratio of used 
Eudragit S and also the solvents in which Eudragit RL 
and RS were suggested to prepare sustained release 
microcapsules (Kibria and Jalil, 2008; Ghaffari et al., 
2011). Compatibility of Eudragits with tramadol was 
established before by Shinde et al. (2008). 
Conclusion 
 
The polymers used in this study are used widely in 
pharmaceuticals to control the release of drug. The 
approach of the present study was to evaluate the effect 
of type and ratio of polymer and plasticizers on the 
characters of desired sustained release pellets. It seems 
that Eudragit could be a suitable choice to prepare 
sustained release pellets containing Tramadol and with 
decreasing of drug taking intervals, the desired system
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Figure 4. Drug release profile through formulation F10 - F21 in medium of acid and then 
PBS (pH: 6.8). 
 
 
 
 
Figure 5. Drug release profile through formulation F24 - F27 in water medium. 
 
 
 
 
 
Figure 6. Drug release profile through formulation F"14 - F"18 in medium of acid and then 
PBS (pH: 6.8). 
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Figure 7. Drug release profile through formulation F16 in medium of acid and then PBS (pH: 6.8). 
 
 
 
could increase compliance of patients and reduce doses 
and drug toxicity. Desired pellets could be filled in hard 
gelatin capsules to take by patients in the future after 
some modifications on drug loading efficiency and scale 
up procedure. 
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The aqueous extract of Terminalia superba leaves was subjected to phytochemical screening. 
Antidiarrhoeal property of the extract was determined at 50, 100 and 150 mg/kg body weight in castor 
oil-induced diarrhoeal Wistar rats. Phytochemical screening revealed the presence of saponins, 
cardenolides, triterpenes, flavonoids, steroids, phenolics and tannins, whereas alkaloids, 
anthraquinones and phlobatanins were not detected. The time of induction of diarrhoea was 
significantly (P < 0.05) prolonged at all the doses of the extract. The frequency of stooling and feacal 
parameters (total number of feaces and number of wet feaces), intestinal fluid accumulation 
(enteropooling) and the weight of intestinal content were significantly reduced. The data in the present 
study indicate that the aqueous extract of T. superba leaves possessed antidiarrhoeal properties. 
 
Key words: Phytochemicals, Terminalia superba, aqueous extract, diarrhoea, rats.  
 
 
INTRODUCTION 
 
Diarrhoea is an increase in the frequency of bowel 
movements, a common cause of death in developing 
countries (including Nigeria) and a second common 
cause of infant deaths worldwide (Schiller and Sellin, 
2010). In the year 2001, diarrhoea claimed 1,793,000 
lives in European countries (Venkat, 2010). In the 
developing world, infectious diarrheoa is a serious life-
threatening illness that results in 4 to 6 million deaths 
each year, mostly in children (Groulez and Wood, 1985). 
Diarrhoea is caused by viruses like rotavirus, norovirus, 
cytomegalovirus and viral hepatitis (Dennehy, 2000; 
Rheingans et al., 2006; Sompson et al., 2007). Other 
causes are bacteria like Escherichia coli, Shigella 
flexneri, and Salmonella spp. (Ryan and Ray, 2004; 
Potter, 2006), parasites (Giardia lamblia, Entamoeba 
histolytica and Cryptosporidium) and adverse  reaction  to  
medicines or food (Santosham et al., 1997). Diarrhoea is 
managed in a variety of ways. These include the use of 
drugs such as antibiotics like loperamide, diphenoxylate, 
atropine, and host of others. Nutrition and supplements 
have also been used (Ehrlich, 2010). Certain astringent 
herbs such as Rubus fruticosus, Rubus idaeus, 
Matricaria recuitta, and Althea officialis have been used 
for the treatment of diarrhoea (Ehrlich, 2010). 
Terminalia superba is a large tree in the family 
Combretaceae claimed locally to possess antidiarrhoeal 
activity. It grows up to 60 m tall, with a domed or flat 
crown and a trunk typically clear of branches for much of 
its height, buttressed at the base. In Nigeria, it is 
widespread, where it is used for making chewing sticks 
and furniture (Groulez and Wood, 1985). In this research, 
aqueous extract  of  T. superba  leaves  was  investigated  
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for the treatment of diarrhoea in Wistar rats. 
 
 
MATERIALS AND METHODS 
 
Plant material 
 
T. superba was collected from Ilesa town in Oriade Local 
Government Area, Osun State, Nigeria. The dried powdered (250 
g) of T. superba leaves was soaked in 1000 ml of distilled water for 
24 h. It was filtered using Muslin cloth and then suction pumped 
with Watchman No. 2 filter paper and air-dried in Petri dishes. The 
residual powder from each Petri dish was then scooped and then 
reconstituted in distilled water to prepare different doses (50, 100 
and 150 mg/kg body weight) that were administered to different 
groups of animals. 
 
 
Experimental animals 
 
Wistar rats (Rattus norvegicus) of both sexes weighing 157.40 ± 
14.68 g used in this experiment were purchased from Ayo Ola 
farms, Ilorin, Kwara State, Nigeria.   
 
 
Qualitative phytochemical screening 
 
The qualitative phytochemical screening of T. superba leaves was  
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carried out as described by Odebiyi and Sofowora (1978) and 
Sofowora (1993) for the detection of tannins, saponins, phenolics, 
alkaloids, steroids, cardiac glycosides, flavonoids, anthraquinones, 
terpenoids and cardenolides. 
 
 
Castor oil-induced diarrhoea 
 
Diarrhoea was induced in the rats by the process as described by 
Gerald et al. (2007). The rats were fasted for 18 h prior to the 
experiment but were allowed free access to water. Twenty-five rats 
were grouped into five containing five rats each. Group I (negative 
control) was administered orally with 1 ml of distilled water while 
group II (positive control) was orally administered with 2.50 mg/kg 
body weight of loperamide chloride. Groups III, IV and V were 
administered with 50, 100 and 150 mg/kg body weight of aqueous 
extract of T. superba leaves.  At the 30 min post-treatment, each 
animal from all the groups was orally administered 1 ml of castor oil. 
The time between oil administration and appearance of the first 
diarrhoeal feaces was noted. Observations for determining the 
severity of diarrhoea were accessed for 6 h by monitoring the 
diarrhoeal feaces on a pre-weighed white paper placed beneath the 
individual rat cages. The total number of feaces, diarrhoeal feaces 
and total weight of feaces excreted were expressed as average and 
compared with the controls. The percentage inhibition of diarrhoeal 
feaces in each group was calculated using the following equation: 
 
 
 
 
 
Castor oil-induced enteropooling 
 
Intestinal fluid accumulation was determined by the method 
described by Havagiray et al. (2004). Twenty-five rats were divided 
into five groups of five animals each. Group I (negative control) 
received 1 ml of distilled water while group II (positive control) 
received loperamide at a dose of 2.50 mg/kg body weight. The test 
Groups III, IV and V were administered the aqueous extract of T. 
superba leaves at oral doses of 50, 100 and 150 mg/kg body 
weight. Castor oil (1 ml) was immediately orally administered to 
each of the rats in all groups. After 30 min, the rats were sacrificed 
according to the method of Yakubu et al. (2005) and the small 
intestine from the pylorus to the caecum was isolated. The intestinal 
contents were collected by milking into a graduated measuring 
cylinder, weighed and their volume measured. 
 
 
Statistical analysis 
 
The results were analyzed for statistical significance using one-way 
analysis of variance (ANOVA) followed by Duncan multiple range 
tests. P < 0.05 was considered significant. 
 
 
RESULTS 
 
The phytochemical qualitative analysis of the aqueous 
extract of T. superba leaves revealed the presence of 
saponins, cardenolides, triterpenes, flavonoids, steroids, 
phenolics and tannins whereas alkaloids, anthraquinones  
and phlobatanins were not detected (Table 1). 
In the castor oil-induced diarrhoeal experiment, the 
aqueous extract of T. superba leaves significantly 
prolonged (P < 0.05) the time of diarrhoeal induction. The 
highest dose of the extract (150 mg/kg body weight) has 
the most significant time of diarrhoeal induction. The 
frequency of stooling and faecal parameters (total 
number of feaces and number of wet feaces) decreased 
significantly compared with distilled water-treated ani-
mals. Similarly, the fresh weight and water content of the 
feaces decreased significantly with a greater reduction in 
these parameters at 150 mg/kg body weight when com-
pared with water-treated animals. Inhibition of defecation 
was significantly increased in extract-treated animals 
compared with the water-treated ones (Table 2). 
There was a significant decrease (P < 0.05) in the 
masses and volumes of the intestinal content in the 
extract-treated animals compared with distilled water-
treated animals. The decrease was dose dependent. 
Similarly, the percentage inhibition of the intestinal 
content of animals treated with the extract increased 
dose dependently with 150 mg/kg body weight of the 
extract producing the highest percentage of inhibition of 
intestinal content. The percentage inhibition in animals 
treated with 150 mg/kg body weight is compared 
favourably with loperamide-treated animals (Table 3). 
 
 
                       No. of diarrhoeal feaces in control –  No. of diarrhoeal feaces in treated rat    
                                                         No. of feaces in control 
 
 
= 
 
% Inhibition 
 
×  100 
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Table 1. Qualitative phytochemical results of the aqueous extract of 
T. superba leaves. 
 
Phytochemical Status 
Saponins + 
Alkaloids _ 
Cardenolides + 
Anthraquinones _ 
Phlobatanins -- 
Triterpenes + 
Flavonoids + 
Steroids + 
Phenolics + 
Tannins + 
 
(+), Present; (-), absent. Results are means ± SEM of three 
determinations. 
 
 
Table 2. Time of induction and frequency of stooling due to the effect of aqueous extract of T. superba leaves against castor oil-
induced diarrhoeal rats. 
 
                           Dose  
Parameter 
Water 
(1 ml) 
Loperamide 
(mg/kg body weight) 
Plant extract 
(mg/kg body weight) 
0 2.5 50 100 150 
Onset time (min) 35.46 ± 0.43
a
 - 50.13 ± 0.05
b
 55.44 ± 0.01
c
 65.41 ± 0.07
c
 
Total no. of feaces 18.13 ± 0.04
a
 2.00 ± 0.02
e
 14.54 ± 0.08
b
 5.76 ± 0.04
c
 4.33 ± 0.09
d
 
Number of wet feaces 5.45 ± 0.06
a
 0.86 ± 0.01
e
 5.21 ± 0.01
b
 3.01 ± 0.06
c
 1.00 ± 0.03
d
 
Fresh weight of wet feaces (g) 2.32 ± 0.02
a
 0.42 ± 0.02
e
 2.23 ± 0.07
b
 2.09 ± 0.02
c
 1.32 ± 0.02
d
 
Water content of feaces (ml) 1.14 ± 0.03
a
 0.19 ± 0.04
e
 1.12 ± 0.03
b
 1.02 ± 0.04
c
 0.64 ± 0.08
d
 
Inhibition of defeacation (%) 0.00
a
 84.22
e
 4.40
b
 44.77
c
 81.65
d
 
 
Values are means ± SD of five determinations. Values carrying different superscripts from the control are significantly different (P < 0.05). 
 
 
 
Table 3. Anti-enteropooling activity of aqueous extract of T. superba leaves on castor oil-induced diarrhoeal rats. 
 
                                  Dose  
Parameter 
Water 
(1 ml) 
Loperamide 
(mg/kg body weight) 
Plant extract 
(mg/kg body weight) 
0 2.5 50 100 150 
Mass of intestinal fluid (g) 1.41 ± 0.02
a
 1.00 ± 0.07
e
 1.11 ± 0.02
b
 1.07 ± 0.04
c
 1.02 ± 0.03
d
 
Volume of intestinal fluid (ml) 1.60 ± 0.05
a
 1.05 ± 0.06
e
 1.37 ± 0.01
b
 1.08 ± 0.03
c
 1.06 ± 0.01
d
 
Inhibition of mass intestinal content (%) - 29.08
b
 21.28
e
 24.11
d
 27.66
c
 
Inhibition of volume intestinal content (%) - 34.38
b
 14.38
d
 32.50
c
 33.75
b
 
 
Values are mean of five determinations ± SD. Values carrying different superscripts from the control are significantly different (P < 0.05). 
 
 
 
DISCUSSION 
 
T. superba is used in the traditional system in managing 
diarrhoea by traditional medicine practitioners mostly in 
Western Nigeria. The present study sought to assess the 
antidiarrhoeal activity of aqueous extract of T. superba 
leaves. Our findings showed that the extract inhibited 
significantly (P < 0.05) castor oil-induced diarrhoea in 
Wistar rats. 
It has been observed that the most active component of 
castor oil, ricinoleic acid produces an irritating action that 
stimulates the peristaltic activity of the small intestine 
(Rouf et al., 2003). This causes changes in the electroly-
tic permeability of the intestinal mucosa (Rouf et al., 
2003). Its effect also caused the liberation of several 
endogenous mediators such as prostaglandins, which 
stimulates motility and secretion, thereby decreasing the 
absorption of sodium and potassium  ions  (Zavala et  al.,  
 
 
 
 
1998; Rouf et al., 2003); and nitric oxide, which has been 
claimed to contribute to the diarrhoeal effect of castor oil 
(Mascolo, et al., 1996). 
The prolonged time of induction of diarrhoea, 
decreased frequency of stooling and faecal parameters 
(total number, fresh weight, water content and number of 
diarrhoeal faeces) observed with the extract in this study 
are indications of antidiarrhoeal potential. The inhibition 
of castor oil-induced intestinal fluid accumulation 
(enteropooling) and the weight of the intestinal content 
may be due to the ability of he extract to increase the re-
absorption of electrolytes and water as also observed 
with the standard drug, loperamide. It can also be 
assumed that the antidiarrhoeal action of the extract was 
mediated by an antisecretory mechanism. The findings in 
this research agree with those of Tangu and Yadav 
(2004) and Appidi et al. (2010).  
Antidiarrhoeal properties of medicinal plants may be 
due to bioactive agents such as tannins, flavonoids, 
steroids and terpenoids (Havagiray et al., 2004; 
Venkatesan et al., 2005). Others include alkaloids, 
saponins and reducing sugar (Longanga et al., 2000). For 
instance, the antidiarrhoeal activity of tannins has been 
ascribed to their ability to denature proteins in the in-
testinal mucosa by forming tannates that make intestinal 
mucosa more resistant to chemical alteration, thereby 
reducing secretion (Havagiray et al., 2004). In addition, 
flavonoids are known to inhibit intestinal motility and 
hydro-electrolytic secretion (Perez et al., 2005). 
 
 
Conclusion 
 
T. superba leaves exhibit antidiarrhoeal activity in the 
pharmacological models used, and thus, its use in 
traditional medicine is justified. The dose related 
antidiarrhoeal activity shown by the aqueous extract of T. 
superba leaves probably suggests the presence of some 
active ingredients (phytochemicals), which act through 
one or more antidiarrhoeal protecting mechanism. 
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The determination of bioequivalence is very important in the pharmaceutical industries because the 
regulatory agencies like the Food and Drug Administration (FDA) allow a generic drug to be marketed 
only if its manufacturer can demonstrate that the generic product is bioequivalent to the brand-name 
product. Up to date, there is a lack of widely accepted statistical procedure for assessing population 
bioequivalence. We propose multilevel models (MLMs) for evaluating and estimating parameters to 
assess population bioequivalence (PBE), and compare statistical properties of PBE estimators between 
MLMs and current approaches recommended by the FDA-the method of moment (MOM) and REML. The 
approach developed is illustrated using a real data set from the FDA. Statistical properties of MLM 
estimators are further explored using simulation studies as compared with MOM and restricted 
maximum likelihood (REML) estimators. The performance of MLM appeared to be much comparable to 
the existing REML procedure. The results suggest that MLM estimators that are fully comparable with 
REML estimators can be an adequate approach for assessing PBE. The MLMs approach proposed in 
the study provides an alternative and yet more flexible and powerful method than existing methods in 
assessing bioequivalence (BE) for complex study designs and data structures.  
 
Key words: Population bioequivalence, multilevel models, simulation, estimation procedure, restricted iterative 
generalized least square (RIGLS), restricted maximum likelihood (REML), method of moments (MOM), food 
and drug administration (FDA). 
 
 
INTRODUCTION 
 
The goal of a bioequivalence study is to show that two 
formulations of a drug have similar bioavailability (Ashby, 
2006). The determination of bioequivalence is very 
important in the pharmaceutical industries because the 
regulatory agencies like the United States Food and Drug 
Administration (FDA) allow a generic drug to be marketed 
only if its manufacturer can demonstrate that  the  generic 
product is bioequivalent to the brand-name product. 
Thus, the design, performance and evaluation of 
bioequivalence studies have received major attention 
among the health authorities and pharmaceutical 
industry, as well as, statisticians (Ashby, 2006; Blume and 
Midha, 1993). 
During the last few decades, the assessment of average
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bioequivalence (ABE), which emphasizes comparing the 
means of two drug formulations has been well 
established (Ashby, 2006; Chen et al., 2000, 2001). The 
major concern was then of course how population 
bioequivalence (PBE) and individual bioequivalence (IBE) 
should be statistically assessed (Chow and Liu, 2008; 
Davit et al., 2008). In contrast to ABE, PBE requires 
equivalence on both the averages as well as variances, 
whereas IBE not only requires equivalence on similarity 
of averages and variances, but also on the homogeneity 
of subject-by-formulation interaction. In 2001, The FDA 
guidance recommended the use of the method of 
moments (MOM) for variance component estimation, as 
well as, the restricted maximum likelihood (REML) 
estimation of data including random missing records 
based on a two-sequence, four-period (2 × 4) cross-over 
design (Carrasco and Jover, 2003). 
During the last decade, although, ABE is now a 
relatively matured field and is theoretically well under-
stood, there is still a lack of widely accepted statistical 
procedure for assessing PBE. Many researchers have 
argued that the current FDA's statistical procedures are 
unsatisfactory in terms of their statistical properties 
(Endrenyi et al., 2003; FDA, 2001, 2003; Ghosh and 
Gönen, 2008; Ghosh and Ntzoufras, 2005). In addition, 
complete data sets are not common in bioequivalence 
studies, and MOM estimation is known to be limited in 
such situations. Furthermore, little information regarding 
the statistical test procedure is provided with the 
exception of 2 × 4 cross-over design, while for PBE and 
IBE, McNally et al. (2003) examined the generalized P-
value approach for making inferences concerning the 
FDA-recommended PBE and IBE criteria. Carrasco et al. 
(2003) introduced the structural equation model (SEM) 
approach for parameter estimation and constructing 
criterion to assess IBE. Dragalin et al. (2003) proposed 
the Kullback–Leibler divergence (KLD) approach for 
parameter estimation and defining criterion in evaluating 
PBE and IBE. In 2005, Bayesian methods of assessing 
IBE and PBE using the FDA criteria were proposed 
(Ghosh and Ntzoufras, 2005). However, none of these 
methods are robust and sensitive enough to be accepted 
as the standard approach by current FDA guidance. 
Moreover, since bioequivalence evaluations are often 
based on the logarithmic transformation of AUC and Cmax, 
the FDA consider two drugs to be bioequivalent only if 
they are similar in both AUC and Cmax. It would be better 
to consider a test which included several endpoints 
together. However, none of the proposed methods 
including MOM, REML, SEM or KLD gave examples in 
assessing ABE, PBE and IBE with multiple endpoints. 
Research in this area is almost blank. 
The theory by Harvey (2010) suggested that bioequi-
valence is a natural field to be assessed using MLMs. In 
principle MLMs can easily disentangle multiple variance 
components as well as covariance required by PBE 
assessment. To our knowledge, there was no thoroughly 
study discussing its applications in PBE studies. 
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This paper serves two purposes: (1) to introduce 
multilevel models using restricted iterative generalized 
least square (RIGLS) algorithm in estimating parameters to 
assess PBE, and (2) to compare the statistical properties 
of PBE estimators between multilevel models and two 
current approaches recommended by FDA. Our concern 
is not on the inference of the PBE criterion but merely 
estimating the components in the current FDA-proposed 
PBE criterion. 
 
 
MATERIALS AND METHODS 
 
Current methods for PBE 
 
The 2001 FDA guidance proposed the following aggregated, scaled 
moment-based one-sided null hypotheses as:  
 
  
 
Note that 
 
and , 
 
and 
 
are population means and 
variances in the logarithm scale. For convenience, we define 
 as mean difference,  as total variance 
of T,  as total variance of the R.  and  are 
between-subject variances,  and  are within-subject 
variances respectively for the T and R. The expression is linearised 
as:  
 
  
 
When
  
or 
,
 
. 
is the bioequivalent limit with a recommended value of 1.7448. If 
the upper bound of the 95% one-sided confidence interval of 
criterion for both ln (AUC) and ln (Cmax) are below zero, PBE can be 
claimed. The measure of PBE is a mixture of the mean and 
variance of the ln (AUC) and the ln (Cmax). In the guidance, FDA 
recommended MOM to estimate variance component for complete 
data, as well as, REML estimation for data including missing 
records. After the estimation of the mean difference and the 
variances has been completed, 95% one-sided upper confidence 
bound for a linearised form of the PBE criterion can be obtained. 
FDA indicated that the method for the upper confidence bound 
should be consistent with the method used for estimating the 
variances. 
 
 
Multilevel models (MLMs)  
 
Models and notations  
 
When measurements are repeated on the same subjects, as the 
data from 2 × 4 replicated cross-over design, a 2-level hierarchical 
structure is established. The measurement replicates are regarded 
as level 1 units, and subjects as level 2 units. Therefore, multilevel 
models (MLMs), proposed by Harvey Goldstein could be a powerful 
tool to analyze BE data. For the jth subject at ith replicate, we  can  fit 
2 2 2
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Table 1. Variance components for PBE criteria in multilevel model. 
 
Parameter Drug R Drug T 
Between-subject  (Level 2) 2 20 ( )u BRσ σ  2 20 01 12u u uσ σ σ+ + 2( )BTσ  
Within-subject   (Level 1) 2 24 ( )e WRσ σ  2 25 ( )e WTσ σ  
Total 2Rσ  
2
Tσ  
 
 
a two-level random slope model in which factors for sequence and period are included, and the variances for T and R groups are defined at 
level 1 as: 
 
 
 
X1 = 1 for drug T and 0 for drug R. 
Z4ij = 1 for drug R and 0 for drug T. 
Z5ij = 1 for drug T and 0 for drug R. 
 
The intercept term is denoted by β0 which estimates the mean of 
drug R, and the slope  estimates the difference of means 
between T and R, (that is, ). The ‘βs’ are 
always referred to as “fixed” parameters of the model, such as 
period and sequence effects. What makes the two-level model 
different from standard linear regression model are the additional 
random effect, ‘us’ and ‘es’. The ‘us’ parameters denote the residual 
in level 2, and the ‘es’ denote the residual in level 1.  
 
 
Variance components for PBE criteria 
 
To obtain variance components of PBE as shown in Equation 2, we 
can specify the level 2 variance as function of  as represented: 
 
 
 
Thus, the level 2 variance of between subjects for drug R (x1 = 0) is
, and   for drug T (x1 = 1). Since a 
subject cannot take both test and reference drug in each 
measurement, so . Hence, the level 1 variance 
(or within-subject) for drug R (Z4ij = 0, Z5ij = 1) is: 
 
 
 
for drug T (Z4ij = 0, Z5ij = 1) is: 
 
 
 
The total level 1 variance is: 
 
 
 
The total variance of R is: 
  
 
 
The total variance of T is: 
 
 
  
The variance components in the model above are summarized in 
Table 1. 
 
 
Parameter estimation methods in MLMs  
 
Goldstein and his colleagues developed the MLwiN software 
package (Version 2.23, Centre for Multilevel Modeling, University of 
Bristol, UK) for multilevel modeling (Rashbash et al., 2008). MLwiN 
uses the iterated generalized least squares (IGLS) and restricted 
iterated generalized least squares (RIGLS) algorithms to estimate 
parameters (Goldstein, 1986, 1989). In considering the small size of 
samples in both the illustrative example and our simulation data, we 
used RIGLS algorithm for all multilevel models presented in the 
paper. It is noted that we also use the term MLMs and RIGLS 
exchangeable for convenience throughout the paper.  
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Table 2. Parameter estimations (SE) from fitting multilevel models. 
 
Parameter ln (AUC) ln (Cmax) 
Fixed effect   
  0β intercept  7.823(0.325) 5.894(0.370) 
  1β treatment  -0.043(0.060) -0.109(0.074) 
2β sequence  -0.186(0.204) -0.302(0.231) 
3β period  0.047(0.020) 0.056(0.027) 
 
Random effect   
  Level 2 (subject)   
  
2 2
0 ( )u BRσ σ  0.366(0.093) 0.478(0.126) 
  
2
1uσ  0.053(0.034) 0.060 (0.053) 
  01uσ  -0.009(0.039) -0.035(0.058) 
 
 Level 1 (replicate)   
  
2
WRσ  0.065(0.015) 0.119(0.028) 
2
WTσ  0.094(0.022) 0.165(0.038) 
 
 
 
Table 3.  Comparison of three methods in variance components estimates. 
 
Variance component ln (AUC) 
 
ln (Cmax) 
MOM REML MLM MOM REML MLM 
2
BTσ  0.400(0.096) 0.400 (0.107) 0.401(0.105) 0.472 (0.113) 0.468(0.133) 0.468(0.129) 
2
BRσ  0.378(0.090) 0.366(0.095) 0.366(0.093) 0.515 (0.123) 0.478 (0.129) 0.478(0.126) 
2
WTσ  0.098 (0.024) 0.094(0.022) 0.094(0.022) 0.171 (0.041) 0.165(0.039) 0.165(0.038) 
2
WRσ  0.067 (0.016) 0.065 (0.015) 0.065(0.015) 0.126 (0.030) 0.119 (0.028) 0.119(0.028) 
PBEν  -0.723 -0.686 -0.691 -1.106 -0.996 -1.019 
95 percent upper bound -0.360 -0.355 -0.431 -0.603 -0.524 -0.650 
 
* The MLM’s 95 percent one-sided upper bound was estimated using asymptotic normal procedure. 
 
 
 
An illustrative example 
 
To demonstrate the methods described in this paper, we acquired 
data set 17a for drug#17: Antihypertensive on the FDA website, 
http://www.fda.gov/drugs/scienceresearch/researchareas/biostatisti
cs/ucm081434.htm. It is a 2 × 4 cross-overdesign (RTTR and 
TRRT) with 19 and 18 subjects per sequence. Thus, there are two 
replications for each drug. The two response variables are the 
natural logarithm of the reported value for AUC and Cmax. We fitted 
two MLMs in MLwiN by using Equation 4 for ln(AUC) and ln(Cmax) 
respectively. The results obtained are presented in Table 2. Since 
total variance of the R group for both ln(AUC) and ln(Cmax) in this 
case were greater than 0.04, that is, , 
the reference–scaled (FDA, 2001) was used to test for the PBE 
criterion. We compared the  scale  calculated  based  on  parameter 
estimates from the MOM, REML and RIGLS in MLM. As shown in 
Table 3, the estimators of variance components in REML and MLM 
are similar, while MOM provided slightly larger estimations .Using 
all the aforementioned methods, the upper bounds of the 95% one-
sided confidence intervals for both ln(AUC) and ln(Cmax) are less 
than 0, so PBE can be claimed.  
 
 
Simulation study 
 
Study design  
 
The simulation study was designed to investigate the performance 
of RIGLS estimation in multilevel models in comparison to that of 
MOM and REML. We simulated log-transformed data for the two 
sequence (TRTR/RTRT), replicated design assuming a sample size  
2 2 2
ˆ ˆ ˆ= >0.04R BR WRσ σ σ+
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Table 4. Parameter settings for simulations (n=36, 0.9ρ = , 500 runs per scenario). 
 
Scenario ∆
 WT WRσ σ=  BT BRσ σ=  
1 
0.05 
0.3 0.3 
2 0.3 0.6 
3 0.5 0.5 
4 0.5 1.0 
    
5 
0.223 
0.3 0.3 
6 0.3 0.6 
7 0.5 0.5 
8 0.5 1.0 
 
 
 
of 36 subjects, 18 per sequence. This sample size corresponded to 
the illustrative example earlier mentioned, which also represented a 
moderate study size suggested in the FDA guidance.  
 
 
Scenarios to be investigated  
 
Scenarios were assumed based on drugs with typical 
characteristics and statistical distributions in practice and in 
previous studies. Six different parameters are to be defined to 
generate sample datasets for the simulation: 
 and ρ. Following other examples, we 
assumed same standard deviation for the two formulations, namely 
 and (FDA, 2001; Endrenyi et al., 2000). 
We then considered the values for =0.05 and ln1.25 
(≈0.223), which corresponds to two prototypical situations in ABE 
studies, and were also used in the simulation research of PBE in 
the GlaxoSmithKline technical report by Patterson and Jones 
(2002).  
 The log-transformed parameters  and  can be 
calculated from the within-subject coefficients of variation (CV) on 
the original scale using the equation: 
 
 
 
A CV of 30% is generally considered the threshold for a highly 
variable drug or drug product (HVD). In 2003 to 2005, the FDA’s 
Office of Generic Drugs (OGD) reviewed 1010 acceptable 
bioequivalence studies of 524 different drug products. Among them, 
the highest CV was 55% (Davit et al., 2005). Since the topic of BE 
for highly variable drugs is one that has been intensely debated in 
many recent articles, conferences and meetings nationally and 
internationally (Haidar et al., 2008), our simulations were conducted 
for moderate high and very high variability products with CV of 30 
and 55% respectively, which derives the values for  and  
approximately 0.3 and 0.5. 
In many studies,  and  are generally larger than  
and (Riviere and Papich, 2009; Willavize et al., 2006), we 
considered scenarios including cases where the  and  
ranged from 1 to 2 times greater than the  and .This 
range was also used by the sample size determination tables for 
PBE given in the Appendix of the FDA guidance document, and it 
also appeared to correspond to some retrospective analyses of 
AUC in replicate cross-over bioequivalence studies.  
Finally, all scenarios considered a strong correlation ρ between R 
and T at 0.9. The reason for examining cases with such seemingly 
high correlation is that responses within a subject to different 
formulations of the same drug are still likely to have a strong degree 
of correlation even if the formulations are only borderline 
bioequivalent (Shao et al., 2000).  
In summary, given the consideration of six parameters, eight 
scenarios were generated (Table 4). The chosen parameter values 
were considered to be representative of typical bioequivalence data 
and these are quite natural and common in practice.  
 
 
Data generation and data analysis 
 
For each scenario, 500 samples were simulated using SAS 
(Version 9.1.3, Cary, NC). We used SAS to perform MOM and 
REML estimation procedures and fitted MLMs using RIGLS 
procedure in MLwiN. Performances of different estimation 
procedures were evaluated using the following quantities that are 
frequently regarded as benchmark accuracy and precision 
measures; bias, mean square error (MSE) and coverage of 95% 
confidence interval.  
 
 
SIMULATION RESULTS  
 
The summarized results of parameter estimates, bias, 
MSE and CI coverage from 500 run samples were shown 
in Table 5 and Figures 1 to 3. 
 
 
Parameter estimates  
 
From Table 5, we observed that all three estimation 
procedures yielded same values of  for all scenarios. 
The estimates of variance components are close to their 
true values from all three methods. In nearly every 
WR WT BR BTσ σ σ σ∆, , , ,
WT WRσ σ= BT BRσ σ=
T Rµ µ∆ = −
WRσ WTσ
2ln(1 )WR WT CVσ σ= +=
WRσ WTσ
BRσ BTσ WRσ
WTσ
BRσ BTσ
WRσ WTσ
∆
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Table 5. Parameter estimates of MOM, REML and MLM (RIGLS) from 500 runs. 
 
Scenario Parameter  
settings 
MOM 
. 
. 
REML 
 
MLM 
Mean 
estimation 
Standard 
error 
Mean 
estimation 
Standard 
error 
Mean 
estimation 
Standard 
error 
1 
0.05∆ =
 0.052 0.046 0.052 0.046 0.052 0.046 
2 0.09BRσ =  0.095 0.034 0.092 0.033 0.093 0.032 
2 0.09BTσ =  0.092 0.036 0.090 0.035 0.092 0.033 
2 0.09WRσ =  0.091 0.021 0.088 0.020 0.087 0.019 
2 0.09WTσ =  0.093 0.022 0.090 0.021 0.089 0.019 
        
2 
0.05∆ =  0.052 0.055 0.052 0.055 0.052 0.055 
2 0.36BRσ =  0.375 0.101 0.364 0.098 0.364 0.098 
2 0.36BTσ =  0.369 0.103 0.359 0.100 0.359 0.100 
2 0.09WRσ =  0.091 0.021 0.088 0.020 0.088 0.020 
2 0.09WTσ =  0.093 0.022 0.090 0.021 0.090 0.020 
        
3 
0.05∆ =  0.054 0.076 0.054 0.076 0.054 0.076 
2 0.25BRσ =  0.264 0.095 0.257 0.093 0.259 0.088 
2 0.25BTσ =  0.256 0.099 0.249 0.096 0.255 0.091 
2 0.25WRσ =  0.252 0.058 0.244 0.056 0.241 0.053 
2 0.25WTσ =  0.259 0.060 0.251 0.057 0.246 0.054 
        
4 
0.05∆ =  0.053 0.092 0.053 0.092 0.053 0.092 
2 1BRσ =  1.041 0.279 1.012 0.272 1.011 0.271 
2 1BTσ =  1.026 0.286 0.997 0.278 0.998 0.278 
2 0.25WRσ =  0.252 0.058 0.244 0.056 0.244 0.056 
2 0.25WTσ =  0.259 0.060 0.251 0.057 0.250 0.057 
        
5 
0.223∆ =  0.225 0.046 0.225 0.046 0.225 0.046 
2 0.09BRσ =  0.095 0.034 0.092 0.033 0.093 0.032 
2 0.09BTσ =  0.092 0.036 0.090 0.035 0.092 0.033 
2 0.09WRσ =  0.091 0.021 0.088 0.020 0.087 0.019 
2 0.09WTσ =  0.093 0.022 0.090 0.021 0.089 0.019 
        
6 
0.223∆ =  0.225 0.055 0.225 0.055 0.225 0.055 
2 0.36BRσ =  0.375 0.101 0.364 0.098 0.364 0.098 
2 0.36BTσ =  0.369 0.103 0.359 0.100 0.359 0.100 
2 0.09WRσ =  0.091 0.021 0.088 0.020 0.088 0.020 
2 0.09WTσ =  0.093 0.022 0.090 0.021 0.090 0.020 
        
7 
0.223∆ =  0.227 0.076 0.227 0.076 0.227 0.076 
2 0.25BRσ =  0.264 0.095 0.257 0.093 0.259 0.088 
2 0.25BTσ =  0.256 0.099 0.249 0.096 0.255 0.091 
2 0.25WRσ =  0.252 0.058 0.244 0.056 0.241 0.053 
2 0.25WTσ =  0.259 0.060 0.251 0.057 0.246 0.054 
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Table 5. Contd. 
 
8 
0.223∆ =  0.226 0.092 
 
0.226 0.092 
 
0.226 0.092 
2 1BRσ =  1.041 0.279 1.012 0.272 1.011 0.271 
2 1BTσ =  1.026 0.286 0.997 0.278 0.998 0.278 
2 0.25WRσ =  0.252 0.058 0.244 0.056 0.244 0.056 
2 0.25WTσ =
 
0.259 0.060 0.251 0.057 0.250 0.057 
 
 
 
corresponding estimates from REML and RIGLS (we use 
the term exchangeable with MLMs), while the latter two 
showed similar results as expected because RIGLS 
provides REML estimators. In cases of scenarios 1, 3, 5 
and 7 where the between-subject variances are the same 
as within-subject variances, the between-subject 
variances estimated from MLMs are slightly larger than 
that of REML, while the within-subject variances from 
MLM are slightly smaller. This trend is not evident in 
scenarios 2, 4, 6 and 8.  
 
 
Assessment of bias 
 
Figure 1 graphically summarizes the bias of variance 
components versus their true population values. It can be 
scenario, estimates from the MOM were greater than 
seen that the biases for all three methods are rather 
small. However, MOM has the largest biases for both 
between-subject variances and within-subject variances, 
that is consistent with the previous simulation results 
(Patterson and Jones, 2002), whilst REML and RIGLS 
showed similar bias. In Figure 1, we can see that the bias 
for MOM is consistently larger (in magnitude), and 
increases steeply when the variance increases. This 
suggests that compared to RIGLS and REML, the MOM 
seems more prone to overestimate as the drug effects 
become more highly variable. RIGLS and REML 
estimates demonstrated less bias than MOM with similar 
patterns in bias as drug effects change in the simulation. 
 
 
MSE  
 
The MSE from three methods are quite small, suggesting 
good performance of all methods. Overall, the differences 
observed in MSE could be by chance in the simulation 
sample and ignorable in practice. MLM estimates are 
very close to REML with slightly better accuracy or less 
bias in some parameter estimates in certain scenarios 
based on the simulation samples. 
 
 
Coverage of 95% CI  
 
Three methods demonstrated differences in the CI 
coverage   and   those   differences  seemed  grouped  by 
scenarios 1, 3, 5 and 7, and scenarios 2, 4, 6 and 8. So 
we drew Figures 2 and 3 for these situations separately. 
Regarding the four variance components, although, the 
values are different among Figures 2 and 3, they showed 
the same patterns. The coverage of all the four variance 
components are constant, completely unaffected by the 
increasing drug variability. MOM gains the largest 
coverage, while MLM and REML showed similar results 
which are close to the nominated 95% for ,  and
, while for , MLM has the same coverage with 
MOM, which is slightly lower than REML. 
In summary, for the assessment of PBE, we can still 
conclude that the MLM and REML showed similar 
performance characteristics, and the latter two performed 
better than MOM.  
 
 
DISCUSSION 
 
This paper served two purposes; to propose multilevel 
models (MLMs) using the RIGLS algorithm for evaluating 
and estimating parameters to assess PBE, and to 
compare statistical properties of PBE estimators between 
MLMs and current approaches recommended by the 
FDA. To our knowledge, this paper is the first to present 
findings from simulation using the RIGLS algorithm in the 
software package MLwiN to analyze bioequivalence data. 
The results indicate that the performance of MLM 
(RIGLS) appeared to be much comparable to the existing 
REML procedure, because RIGLS is equal to REML in 
large sample (Goldstein, 1989). These two procedures 
are frequently indistinguishable and often provide better 
performance than MOM.  
However, MLM exhibits three advantages over the exis-
ting methods. First of all, it has the ability to decompose 
the total variance into components for complex data 
structure, that is, more than three levels of hierarchy, 
more than two treatment and more than two periods.  
The second advantage is its easy extension for 
assessing not only PBE, but also IBE and ABE. IBE is a 
criterion for deciding if a patient who is currently being 
treated with R can be switched to T. When IBE is con-
sidered, it assesses an aggregate measure involving the 
means and variance of T and R, as well as the subject-
by-formulation interaction. The key difference from PBE is  
2
BRσ
2
BTσ
2
WRσ
2
WTσ
Shen et al.          859 
 
 
 
 
 
Figure 1. The mean bias in the estimates of four variance components by MLM, MOM and REML. BT 
stands for 2BTσ , BR for
2
BRσ , WT for 
2
WTσ ,and WR for
2
WRσ . 
True value 
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Figure 2. Coverages of 95% CI for four variances components according to MLM, MOM and REML on Scenario 
1, 3, 5, 7.  
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Figure 3. Coverages of 95% CI for four variances components according to MLM, MOM and REML on Scenario 
2, 4, 6, 8. 
  
 
 
that IBE assumed individual difference in responding to 
formulation. Such difference can be captured and 
measured by the subject-by-formulation interaction : 
 
 
 
Where  and  are the random subject effect for 
subject j on T and R especially. 
Multilevel model is readily expanded for assessing IBE. 
For instance, consider a two-level random slope model 
as an example, similar to the one we mentioned in 
simulation result. In Equation 4, the random effect is 
the slope residual in subject j, which measured the 
subject-specific increment to the treatment effect. It is 
easy to prove that , 
. Therefore the key ingredient 
in the IBE criteria  can be expressed as , which is 
a variance component in multilevel model. The extension 
of MLMs for assessing IBE is straightforward. A 
preliminary examination of MLMs in BE, including asses-
sing IBE by Shen et al. (2009), has been published most 
recently. As the study only illustrated the MLMs approach 
by applying it on real example, further simulation studies 
to demonstrate the performance of such model in 
assessing IBE will be helpful. 
The third advantage is the flexibility to cover multiple 
endpoints for simultaneous bioequivalence assessment. 
It should be noted that, in the example of FDA dataset 
illustrated in this paper, both AUC and Cmax met the 
criterion for establishment of PBE. However, in practice, it 
is not uncommon to pass AUC but fail Cmax. In this case, 
the regulatory authorities and researchers proposed 
several alternative measures (Wang et al., 1999; Ghosh 
and Gönen, 2008; Chen et al., 2001). One proposal was 
that for highly correlated AUC and Cmax, one should 
obtain a combined estimate of the drug effects by 
considering the two outcomes simultaneously. In a 
multilevel model framework, data with multiple outcomes 
at certain time period within-subject can be viewed as a 
3-level structure: the outcomes measured on each 
occasion are considered nested at the lowest level, within 
replicated measurement (now at level 2) within subject 
(now at level 3). MLMs approach can simply link the 
marginal models of AUC and Cmax through a variance-
covariance structure of the two at level 1 to form a 
simultaneous model to assess either ABE or PBE. 
Further simulation study should be conducted to examine 
performance of multivariate MLMs and the statistical 
features of the parameter estimates. 
This research offers many exciting new directions for 
future research. A number of issues in the proposed 
MLMs approach are the remaining debatable. First of all, 
the 95% upper bound of the linearised PBE criterion in 
this study was calculated based on asymptotically normal  
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assumption. The standard error for each variance 
component and function of a particular variance provided 
directly by the software MLwiN of RIGLS algorithm is 
based on asymptotic properties and may be unreliable 
when sample size is small. The advantage of MLM’s 
capacity to assess IBE or multivariate outcomes would be 
penalized by more complex variance-covariance struc-
ture, more complex criterion, hence more uncertainty in 
the upper bound of the criterion. Recently FDA becomes 
more accepting of Bayesian (Li and Xu, 2011; Ashby, 
2006). The use of the Bayesian approach allows us to 
obtain credible intervals and density plots for both 
random effect variances and standard deviations. The 
MLwiN was built in tools for MCMC and bootstrapping 
modeling. Hence, further research should explore those 
models within the MLMs framework in estimating upper 
bound of the PBE and its extendibility for IBE or 
multivariate MLMs criterion. Other methodological study 
in order to establish the MLMs approach in the BE field 
could be the rate of type 1 error over the effect size, 
sample size determination and the power of test. Further 
investigations in those areas are also suggested.  
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The pharmacokinetic (PK) of omeprazole (OMP), 5-hydroxy-omeprazole (5-OH-OMP) and omeprazole 
sulphone (OMP-SUL), was investigated in healthy premenopausal and postmenopausal females. A 
single oral dose, open-label, non-controlled, pharmacokinetic study was conducted in healthy 
premenopausal (n = 16) and postmenopausal (n = 8) females. The samples were analyzed using 
reversed phase high performance liquid chromatography (HPLC), different pharmacokinetics (PK) 
parameters were determined and compared statistically to evaluate the difference between two groups. 
The activities of CYP2C19 and CYP3A4 were determined as AUCOMP/AUCOH-OMP and AUCOMP /AUCOMP-SUL, 
respectively. The significant differences (P < 0.05) between Cmax, tmax, , , t1/2 and metabolic 
ratios (MR) of OMP, 5-OH-OMP and OMP-SUL were observed between premenopausal and 
postmenopausal females
.
 The present studies showed the higher AUC and longer t1/2 in 
postmenopausal subjects. The increase in MR for 5–OH-OMP and also OMP-SUL determined as AUCOH-
OMP/AUCOMP and AUCOMP-SUL/AUCOMP, respectively, was also observed in postmenopausal females 
compared with the premenopausal females. 
 
Key words: Omeprazole, pharmacokinetics, menopause. 
 
 
INTRODUCTION 
 
The perimenopause and menopause are associated with 
manifestation of hyperacidity, along with hot flashes 
(Pachman et al., 2012; Machowska et al., 2004), 
depression and insomnia (Cuadros et al., 2012; Freeman 
et al., 2007). Postmenopausal females have higher pro-
pensity for gastric hyperacidity (Machowska et al., 2004), 
which is associated with increased use of gastric anti-
secretary drugs including proton pump inhibitors (PPIs). 
The increased risk of hip bone fracture has been reported 
in postmenopausal females, accompanied with the use of 
OMP (Roux et al., 2009). Menopause is associated with 
hormonal transitions (Davison et al., 2005), which affects 
metabolism of drugs (Simpson and Davis, 2001) and  this  
may lead to altered pharmacokinetics (PK) in 
postmenopausal females. 
The OMP is metabolized in the liver by CYP2C19 to 5-
OH-OMP (70%) (Andersson et al., 1994; Karam et al., 
1996; Cederberg et al., 1989) and by CYP3A4 into OMP-
SUL (30%) and a major secondary metabolite is hydroxyl 
sulphone (OH-SUL) obtained from 5-OH-OMP and OMP-
SUL (Andersson et al., 2012).  
PK of OMP has been accomplished considering gene-
tic polymorphism (Andersson, 1990; Ramsjö, 2010) racial 
or interethnic differences (Kim et al., 2004; Ieiri et al., 
1996), and population PK (Gonzalez et al., 2003; Chang 
et al., 1995), but in these studies PK were evaluated without 
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Table 1. Demographic characters of pre and postmenopausal 
subjects. 
 
Group  Pre (n=16) Post (n=8) 
Age (years) 24.0±0.30 55.90±0.74* 
Weight (kg)
 
52.60±2.13 66.50±2.04 
Height (cm)
 
148±3.2 150.40±5.1 
BMI  24.5±0.43 29.6±0.52 
 
*Significant at P<0.05; NS, Non significant; Pre, premenopausal 
females; Post, postmenopausal females; BMI, body mass index. 
Demographic characters have been shown 
 
 
 
considering genders differences or menopausal status of 
females. Though, PK profile of OMP has been 
investigated in males; however, in females it is obscure, 
including the postmenopausal females and this needs 
further exploration (Sakai et al., 2001). Different 
variables, which may affect PK and clinical outcome of 
drugs, must be investigated in order to optimize the dose 
regimen (Weston and Hood, 2004).  
The relationship between the CYP2C19 genotype and 
PK of OMP in elderly people was established; however, 
menopause or gender difference was not considered as a 
potential factor (Ishizawa et al., 2005). The extensive 
literature survey reveals that available data on the subject 
of PK of OMP is not sufficient to explain or predict PK of 
OMP in postmenopausal females. 
This study was conducted to investigate the PK 
differences for OMP and its metabolites 5-OH-OMP and 
OMP-SUL, as well as to determine the differences of 
activities of CYP2C19 and CYP3A4 between premeno- 
pausal and postmenopausal female. 
 
 
MATERIALS AND METHODS 
 
An optimized and validated high performance liquid 
chromatography-ultraviolet (HPLC-UV) method was used for 
quantitative analysis of OMP, 5-OH-OMP and OMP-SUL (Ahmad et 
al., 2011). The applied method was validated by determining accu-
racy, precision, sensitivity and specificity (validation parameters are 
shown in Table 3 and Table 6). A HPLC system of Perkin Elmer 
Series 200 (Norwalk, USA), operational with online vacuum 
degasser, Perkin Elmer Series 200, column oven, and UV-VIS 
detector were used. Total-chrome workstation software (version 
6.3.1) was linked with the LC system by network chromatography 
interface (NCI) 900. 
OMP, 5-OH-OMP, OMP-SUL and pantoprazole, used as internal 
standard (IS), were provided by Astra Zeneca (Sweden) and 
Medicraft (Pvt.) Ltd. (Peshawar, Pakistan), respectively. HPLC 
grade methanol, potassium dehydrogenate phosphate and sodium 
hydroxide (NaOH) were purchased from Sigma-Aldrich (oslo, 
Norway), Fischer Scientific (Leicestershire, UK) and Merck 
(Darmstadt, Germany), respectively. Distilled water prepared by 
Millipore (Milford, USA) distillation apparatus was used throughout 
this study. 
 
 
Study design 
  
A   single   dose,   open-label,  non-controlled,  premenopausal  and  
 
 
 
 
postmenopausal cohort PK study was designed to investigate the 
PK of OMP and the activities of CYP2C19 and CYP3A4 in 
premenopausal (n = 16) and postmenopausal (n = 8) healthy 
female volunteers. This study was conducted in agreement with the 
principles of international conference on harmonization for con-
ducting good clinical practice and declaration of Helsinki. This study 
was approved by ethical committee of Department of Pharmacy, 
University of Peshawar. Application number 13/EC/Pharm.ref 
number 12/Pharm.  
 
 
Selection of volunteers 
 
Healthy premenopausal (n = 16) and postmenopausal (n = 8) 
females were selected. The design and purpose of the study was 
explained to volunteers and a written informed consent was 
obtained. The mean ± standard deviation (SD) age of the 
premenopausal volunteers was 24.0 ± 0.23 years and for post-
menopausal females, it was 55.90 ± 0.74 years. The body weights 
of premenopausal and postmenopausal female volunteers were 
52.60 ± 2.13 and 66.50 ± 2.04 kg, respectively. All premenopausal 
female subjects had a regular menstrual cycle of 28 days. The 
postmenopausal females had entered the menopause completely 
for minimum one year passed after the cessation of their last men-
strual cycle. The overall health status of postmenopausal females 
was satisfactory, free of any gross level pathological evidence, but 
fluctuation in their blood pressures was compromised. The demo-
graphic data of volunteers is shown in Table 1. Prior to inclusion of 
volunteers in the experiment, complete medical histories were 
obtained and full body screening by various laboratory tests was 
performed like blood hemoglobin, serum cholesterol, serum 
bilirubin, serum creatinine, low density lipoprotein (LDL)-cholesterol, 
triglyceride, high density lipoprotein (HDL)-cholesterol, very low 
density lipoprotein (VLDL)-cholesterol to determine their health 
status. The clinical data is shown in Table 2. 
 
 
Drug administration and blood sampling 
 
The subjects were instructed to avoid intake of any medication 
including herbal medicines a week before the study. The volunteers 
were kept on overnight fasting before trial, no juice, caffeine or food 
intake was allowed except water before studies. At about 8.00 AM, 
each volunteer received OMP capsules (40 mg) with a full glass of 
water (ca ≈ 250 ml). The blood samples (≈ 5 ml) were collected 
from cubital vein and occasionally collected from cephalic vein, at 
0.0, 0.5, 1.0, 2, 3, 4, 6 and 8 h. The blood samples were centrifuged 
and the plasma was separately stored at -80°C till analysis. The 
standard breakfast and lunch was served after 3 and 5 h, 
respectively, following the drug administration. 
 
 
Standard solutions 
 
Stock solutions (1 mg/ml) of OMP, 5-OH-OMP and OMP-SUL were 
prepared by dissolving the drug and metabolites in methanol. 
Working solutions were prepared by diluting the stock solution in 
Eppendorf tubes (2 ml) in the concentration ranges of 5 to 500 
ng/ml for each OMP and OMP-SUL, while 10 to 1000 ng/ml for 5-
OH-OMP, respectively. The concentration of internal standard (IS) 
(1 µg/ml) was kept constant in all dilutions. While preparing plasma 
sample, plasma (150 µl) and 50 µl of each of analyte and internal 
standard were taken (Ahmad et al., 2011). 
 
  
Sample preparation 
 
Plasma sample thawed at room temperature and sample (150 µl) 
were transferred to Eppendorf tube. Then pantoprazole, used as an 
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Table 2. Clinical data of pre and postmenopausal female participants of pharmacokinetic 
study of OMP and its metabolites. 
 
Clinical value Unit Pre (n=16) Post (n=16) P value 
Hb gm/dl 14.44±0.23 12.84±0.32 0.0014** 
Serum bilirubin  mg/dl 0.56±0.3 0.77±0.5 0.0021** 
Serum creatinine  mg/dl 0.66±0.05 0.8±0.05 0.1142 
Serum cholestrol  mg/dl 133.8±8.5 144.2±4.2 0.3 
Serum triglyceride  mg/dl 84.63±10.32 114.0±7.8 0.04* 
HDL cholesterol   mg/dl 31.25±4.4 81.13±4.4 0.2 
LDL cholesterol  mg/dl 71.88±5.3 78.5±4.3 0.84 
 
*Significant at   P˂0.05, **Significant at P˂0.005, ***Significant at P<0.0005, Hb, hemoglobin value; 
HDL cholesterol, high density lipid cholesterol; LDL cholesterol, Low density lipid cholesterol. 
 
 
 
Table 3. Pharmacokinetic parameters of OMP (40 mg) following oral administration in pre and postmenopausal female 
volunteers. 
  
PK    Unit OMP P-value 95% confidence interval Pre (n=16)           post (n=8) 
Cmax  µg/ml 2.9±0.60 3.7±0.50 0.003** -1.4 to -0.34 
tmax h 2.3±0.2 2.583±0.4 0.14 -0.60 to 0.10 
  
 
µg.h/ml 8.7±2.24 15.3±2.24* 0.0001*** -12.81to -7.62 
  
µg.h/ml 9.7±3.31 19.38±2.9* 0.0001*** -18.8 to -0.6 
Vd ml/kg 315.4±97.9 469.3±125.1 0.011* -265.5 to -42.3 
CL ml/h/kg 111.6±20.69 58.40±8.62* 0.0001*** 40.5 to 65.5 
t1/2  h 2.3±0.8 2.9±0.24 0.01* -1.06 to -0.2 
 
*significant at   p ˂ 0.05, ** significant at  p ˂  0.005, ***significant at p < 0.0005; PKs ,  pharmacokinetic parameters, compared 
in pre and postmenopausal females for OMP ;Cmax, maximum plasma concentration:tmax, time to achieve the maximum 
plasma concentration;t1/2 ,elimination half life;AUC0-t ,Area under the plasma concentration time curve from 0 time to last 
sampling time;AUC∞ , Area under the plasma concentration time curve from 0 hr to infinity time,Vd,volume of distribution; CL, 
clearence of analyte from body 
 
 
 
internal standard, was added and vortexed for 30 s. Three parts of 
methanol (450 µl) was added, vortexed for further 3 min and then 
centrifuged at 5000 rpm at 0˚C for 5 min. The separated clear layer 
of plasma was transferred to Eppendorf tube (Ahmad et al., 2011). 
 
 
Chromatography 
 
Chromatographic separation was achieved using Supelco/discovery 
C18 (150 × 4.6 mm, 5 µm) analytical columns protected by a Perkin 
Elmer C18 (30 × 4.6 mm, 10 µm; Norwalk, USA), pre-column guard 
cartridge, the temperature of the column was 45°C and the detector 
wavelength was adjusted at 302 nm. The mobile phase, ratio of 
methanol and buffered (pH 7.2) aqueous phase of potassium 
dehydrogenate phosphate (42:58 v/v) were pumped, at the flow 
rate of 0.8 ml/min. Different optimized parameters are shown in 
Table 3. 
 
 
PK analysis 
 
Plasma concentration of OMP, 5-OH-OMP, and OMP-SUL as a 
function of time was plotted on semi-log scale to evaluate various 
PK parameters. The data was also analyzed using PK-Solution® 2.0 
software for non-compartmental data analysis. 
Statistical analysis 
 
The software programme used for statistical analysis was graph 
pad prism 5 and Statistical Package for Social Sciences (SPSS) 16. 
The data was presented as mean ± standard deviation (SD) and the 
difference between various groups was studied using student t-test 
at 95% confidence interval.  
 
 
RESULTS 
 
PK of OMP and its metabolites 
 
Volunteers characteristics 
 
The demographic and clinical data of the volunteers is 
shown in Tables 1 and 2, respectively. The age of 
postmenopausal females was significantly higher when 
compared with the premenopausal females (P < 0.05), 
while the rest of the demographic characters did not 
display any significant difference. Hemoglobin value was 
significantly higher in premenopausal females (P < 0.005) 
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Table 4. Pharmacokinetic parameters of metabolite, 5-OH-OMP following oral administration of OMP (40 mg) in 
pre and postmenopausal female volunteers. 
  
PK Unit 5-OH-OMP P-value 95% CI 
Pre (M) Post (F) 
Cmax µg/ml 1.11±0.2 1.252±0.5 0.02* -0.60 to 0.4 
tmax h 2.62±0.20 3.06±0.34 0.020* -0. 8to -0.099 
 
µg.h/ml 3.13±0.53 3.90±0.7 0.0001*** -1.41 to -0.15 
 
µg.h/ml 3.6±0.73 9.486±2.51* 0.0001*** -7.05 to -4.6 
Vd ml/kg 664.3±110.1 640.1±48.5 0.0001*** 43.09 to 91.7 
CL ml/h/kg 271.3±52.30 93.88±19.8 * 0.0001*** 146.7 to 208.3 
t1/2 h 2.3±0.79 7.64±2.7* 0.0001*** -6.8 to -3.8 
MR AUCOMP 2.8± 0.63 3.72± 1.3 0.06 -1.9 to 0.04 
 
*Significant at p ˂ 0.05, ** significant at p ˂ 0.005, ***significant at p < 0.0005, MR: metabolic ratio, pharmacokinetic 
parameters compared in pre and postmenopausal females for 5-OH-OMP.  
 
 
 
Table 5. Pharmacokinetic parameters of metabolite, OMP-SUL following oral administration of OMP (40 mg) in pre and 
postmenopausal female volunteers. 
 
PKs Unit OMP-SUL P-value 95% CI Pre Post 
Cmax µg/ml 0.25±0.032 0.18±0.082 0.012* 0.030 to 0.2 
tmax Hr 3.5±0.42 4.040±0.8 0.1069 -1.24 to 0.14 
 
µg.hr/ml 0.75±0.2 0.8±0.2 0.3821 -0.3 to 0.11 
 
µg.hr/ml 1.4±0.42 3.653±1.6 0.0062** -3.63 to -0.9 
Vd ml/kg 5155±1715 5996±2051 0.3383 -2676 to 995.6 
CL ml/hr/kg 1527±610.2 779.7±467.3 0.004** 273.4 to 1223 
t1/2 Hr 4.06±1.07 26.58±11.9* 0.0001*** -28.89 to -16.17 
MR AUCOMP /AUCOMP-SUL 13.08± 6.4 18.16± 6.91 0.08 -10.8 to 0.61 
 
*significant at p ˂ 0.05, ** significant at  p ˂  0.005, ***significant at p < 0.0005, MR: metabolic ratio , pharmacokinetic parameters compared 
in pre  and postmenopausal females for  
OMP-SUL. 
 
 
 
while serum bilirubin (P < 0.005) and serum triglyceride 
levels (P < 0.05) were significantly higher in postmen- 
pausal females. Rest of the clinical data also did not 
show any significant difference. Plasma proteins and 
plasma albumins were insignificantly higher in postmen- 
pausal females. 
 
 
Gender based PK analysis of omeprazole and its 
metabolites 5-OH-OMP and OMP-SUL 
 
The plasma OMP, 5-OH-OMP and OMP-SUL concen-
trations as a function of time are shown in Figures 1, 2 
and 3. The PK data of OMP, 5-OH-OMP and OMP-SUL 
between premenopausal and postmenopausal female 
were then compared (results are shown in Tables 3, 4 
and 5). 
In postmenopausal females, 27% increase in Cmax for 
OMP   (P < 0.005)  and  13%  increase  in  tmax,  (P > 0.05)  
compared with the premenopausal females was 
observed. Also, results in the 75% increase in the 
 and 99% increase in the in 
postmenopausal females (P < 0.0005). The elimination 
t1/2 was also significantly (P < 0.05) higher (26% higher) in 
postmenopausal females. The significant increase in 
volume of distribution (Vd) and decrease in clearance of 
analyte from body (CL) of OMP was observed in post-
menopausal women compared with the premenopausal 
female volunteers.  
The Cmax and tmax of 5-OH-OMP were significantly (P < 
0.05) higher in postmenopausal female compared with 
premenopausal females. The metabolic ratios (MR) 
exhibited a 32% raise in postmenopausal females. The 
elimination t1/2 value was significantly higher (232% raise) 
in postmenopausal females, (P < 0.05). Vd and CL 
increased significantly in premenopausal females.  
Cmax of  OMP-SUL decreased up to 28% in postmenopausal 
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Table 6. HPLC Method validation parameters (Ahmad et al., 2011) 
 
Parameter  
Calibration range 
(mg/mL) 
Regression 
equation 
Correlation 
coefficient 
Spiked plasma 
samples 
Regression 
equation 
Correlation 
coefficient 
sensitivity 
Limit of 
detection, LOD 
(ng/mL) 
Limit of 
quantification, 
LOQ (ng/mL) 
OH 0.01–1 Y =1.71 x +0.00 0.999 24.5±0.43 Y = 1.720 x +0.011 0.998 3 10 
5-OMP -OMP 0.05––.5 Y = 3.675 x -0.002 0.999 29.6±0.52 Y = 3.581 x -0.05 0.999 1.5 5 
OMP-SUL 0.05–.5 Y = 4.430 x -0.00 0.999 0.53 Y = 4.234 x +0.027 0.998 1.3 5 
 
 
 
 
 
 
Figure 1. The plasma concentrations of  OMP  as a function  of time in pre and 
postmenopausal females. 
 
 
 
 
 
 
 
Figure 2. The plasma concentrations of 5-OH-OMP as a function of time in pre and 
postmenopausal females. 
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Figure 3. The plasma concentrations of  OMP-SUL as a function of time in pre and postmenopausal 
female. 
 
 
 
females compared with premenopausal females (P < 
0.05) while the tmax was 15% higher in postmenopausal 
females with no significant difference (P > 0.05). 
 increased insignificantly (P > 0.05) in 
postmenopausal females compared with premenopausal 
females. showed a significant 163% rise in 
postmenopausal females. MR was 38% higher in 
postmenopausal females. t1/2 was significantly higher in 
postmenopausal females. The insignificant increase in Vd 
in postmenopausal females was observed. CL of OMP-
SUL was also significantly higher in premenopausal 
females compared with the postmenopausal female 
volunteers. 
 
 
DISCUSSION 
 
The PK differences of OMP, 5-OH-OMP and OMP-SUL 
and the activities of CYP2C19 and CYP3A4 in 
premenopausal and postmenopausal females were 
determined. Menopause is associated with age therefore 
the geriatric dose may not be sufficient for the treatment 
of various ailments in these patients (Schwartz, 2007) 
and there is need for the adjustment of dose or dosage 
regimen (Gurwitz et al., 2005). OMP is a highly 
interactive drug and inhibit various cytochrome P450 
enzymes. It is a potent competitive inhibitor of CYP2C19, 
moderate competitive inhibitor of CYP2C9, very weak 
competitive inhibitor of CYP2D6 (Ko et al., 1997), and 
weak non-competitive inhibitor of CYP3A (Tateishi et al., 
1995). It has no effect on CYP1A2 or 2E1, but it induces 
CYP1A1 (Quattrochi and Tukey, 1993). It is possible that 
OMP may interact with other drugs in multiple drug 
therapy and PK of the drug may vary in old age, 
particularly in postmenopausal female. The physiological 
and biochemical changes that appear in old age are also 
associated with menopause; like slower gastrointestinal 
motility (Graff et al.,  2008),  higher  body  fat  ratio  (Carr,  
2003) and decreased renal clearance (Christiansen et al., 
1971) that may also affect absorption, distribution and 
clearance of xenobiotics in postmenopausal females. 
The Cmax of OMP in postmenopausal was significantly 
higher (P < 0.002) compared with premenopausal 
females and the tmax slightly increased (P > 0.14) in 
postmenopausal volunteers. Similarly, significant 
increase (P<0.0001) in  of the OMP was 
observed in postmenopausal female compared with the 
premenopausal volunteers. The AUC in postmenopausal 
female was increased by 199.78%, that is, revealed by 
the significantly (P<0.0001) higher  in 
postmenopausal females. That may be due to the either 
increase in the absorption of the drug or slower metabo-
lism of the OMP by the postmenopausal female. AUC is 
determined by gastrointestinal absorption, hepatic 
metabolism, first-pass effect and volume of distribution. It 
is known that gastrointestinal motility decreases in 
postmenopausal females (Graff et al., 2008), that may be 
the possible reason for increased systemic absorption of 
OMP. It is also possible that the decrease in the meta-
bolism or decrease in the activities of efflux transporters 
may increase the systemic exposure of the OMP. The 
drugs that are substrate of CYP3A4 or P-gp showed 
higher bioavailability in older females (Krecic-Shepard et 
al., 2000). OMP is a substrate of P-gp which decreased 
in old age and may increase the absorption of the OMP. 
Similarly, the activity of the CYP3A4 also decreased in 
old age (Krecic-Shepard et al., 2000) and may reduce the 
metabolism of the drug and results in higher Cmax. The 
elimination half-life t1/2 was also significantly higher in 
postmenopausal females, suggesting elimination of OMP 
is slower in post-menopausal females. The reduced 
elimination of OMP does not depend on renal 
clearance/function, as orally administered omeprazole is 
metabolized completely and 80% is excreted as 
metabolites in the urine and the remainder 20% is found 
in the feces, primarily originating from bile secretion.  
  
 
 
Therefore, determination of MR plays very important 
role in evaluating the enzymes activities and metabolites 
formation which reflect the conversion of OMP into its 
respective metabolites. MR for both metabolites 
( OMP/ 5-OH-OMP and OMP/  
OMP-SUL, was higher in postmenopausal females when 
compared with the premenopausal subjects; however, 
the difference was not significant. Apparently, it suggests 
that CYP2C19 activity is reduced in postmenopausal 
females. While the ratio of the metabolites ( 5-OH-
OMP/ OMP-SUL), increased significantly from 0.389 to 
2.6 and may be due to significant decrease in the 
CYP3A4 activity in the postmenopausal female as it has 
been observed that the bioavailability of CYP3A4 
substrates is higher in such females (Krecic-Shepard et 
al., 2000). 
The Vd was higher while CL of OMP was lower in 
postmenopausal female when compared with the 
premenopausal and may be due to the plasma protein 
binding of the drug as the OMP is the highly protein 
bound drug (96%). Moreover, the body mass index (BMI) 
and weight were higher in postmenopausal females and 
may be a quite plausible reason for higher Vd in 
postmenopausal females. The change in the protein level 
may also be responsible for higher concentration of 
unchanged drug in the postmenopausal volunteers. 
The 5-OH-OMP displayed higher values for Cmax, 
 and  and tmax in postmenopausal 
females. Previously, no PK study on OMP was conduc-
ted, particularly in postmenopausal females but studies in 
older females suggest that CYP2C19 activity is lower in 
females (Bachmann and Belloto, 1999). The results of 
this study support the previous findings. A significantly 
higher value of t1/2 in postmenopausal females was 
observed. This suggests that CL and Vd of 5-OH-OMP is 
reduced, as is evident from the higher serum creatinine 
value of postmenopausal females, indicating reduced 
glomerular filtration rate (GFR). Aging is associated with 
decrease in all modes of clearance like glomerular 
filtration, tubular reabsorption or secretion (Cockcroft and 
Gault, 1976) and in older females, menopause combined 
with aging, precipitates decrease in renal clearance 
(Christiansen et al., 1971). 
The OMP-SUL Cmax and  displayed a sig-
nificantly higher value in premenopausal females, though 
 values were not significantly higher. The MR for 
OMP and OMP-SUL was higher in postmenopausal fe-
males suggesting an overall decreased metabolic activity 
of CYP3A4 in postmenopausal females. The significantly 
higher value of t1/2 in postmenopausal females suggests 
the same fact that renal CL and Vd were reduced which 
may be due to increase in the serum creatinine level 
leading to reduced GFR.  
Though, in this study, genetic polymorphism of 
volunteers was  not  determined  but apparently  it  is  not 
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affecting the status of the results evaluation. The PK 
studies previously conducted for OMP, neither gender 
based analysis was performed nor menopause was given 
any important consideration and the differences between 
premenopausal and postmenopausal females were not 
ruled out. Though few studies have been conducted 
taking OMP as probe drug to determine CYP2C19 and 
CYP3A4 activities in males and females, but these did 
not provide most of the information regarding female’s PK 
profile (Laine et al., 2000; Zhang et al., 2006).  
 
  
Conclusion 
 
The PK differences of OMP and metabolic activities of 
CYP2C19 and CYP3A4 in premenopausal and 
postmenopausal female volunteers were evaluated. 
These findings suggest that postmenopausal females 
need to be considered as special group of subjects and 
dose should be adjustment if necessary, particularly in 
multiple drug therapy where omeprazole exhibits drug 
interactions.  
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Alchornea cordifolia, a half way growing shrub from Africa is very valued by traditional doctors in 
treating numerous ailments including psychical and nervous troubles. The aim of our study was to 
investigate the anxiolytic activity of A. cordifolia leaves by estimating the effect of an aqueous extract 
of this plant upon the spontaneous movements and the exploratory behaviour of laboratory mouse. 
Study of spontaneous movements (moving, straightening-up, activity duration) was done using an 
activemeter. To assess the exploratory behaviour, a hole-board test was used. The results showed that 
all spontaneous movements as rapid moving, rapid straightening-up as well as activity duration of 
mouse decreased after administration of A. cordifolia in the dose of 2500 mg/kg body weight, p.o. A 
reduction of exploratory behavior in A. cordifolia 2500 mg/kg body weight p.o-treated mice could also 
be noticed. Thus, the present findings suggest that A. cordifolia might be a potential candidate for use 
as an anxiolytic drug in the treatment of neuro-psychical troubles. 
 
Key words: Alchornea cordifolia, anxiolytic activity, spontaneous movement, hole-board test, mouse. 
 
 
INTRODUCTION 
 
In African countries, about 80% of the population de-
pends on traditional medicine for their treatment, because 
it is readily available and affordable economic-wise. 
Alchornea cordifolia (Euphorbiaceae) is a shrub or small 
tree spreading from Senegal to Kenya and Tanzania and 
throughout Central Africa to Angola is highly valued by 
traditional doctors. In addition to its sedative and anti-
spasmodic activities, it is also used to treat a variety of 
respiratory problems, genital-urinary problems, wounds, 
pain, and many others uses. The leaves are also taken to 
treat psychical and nervous troubles (Adjanohoun and 
Ake, 1979). The scientific importance given  to  this  plant  
by many researchers has helped to highlight several 
properties it possess: antibacterial (Ajao et al., 1985; 
Lamikanra, 1990; Lamikanra  et al., 1999; Sutton et al., 
2000; Tona et al., 2000), anti-malarial (Banzouzi et al, 
2002), anti-inflammatory (Manga et al., 2004; Osadebe 
and Okoye, 2003; Mavar-Manga et al., 2008), 
antispasmodics (Ogungbamila and Samuelsson, 1990), 
antioxidant (Nia et al., 2005), and anti-diarrhea (Agbor et 
al., 2004). However, very few studies have been con-
ducted on the activity of this plant on the central nervous 
system. The aim of this study was to investigate the 
anxiolytic  activity  that  A.  cordifolia  leaves  possess by
 
*Corresponding author. E-mail: giselekouakou@yahoo.fr. Tel: (225)07494409. Fax: (225)22486068. 
  
 
 
 
 
measuring its effects on behavior and exploratory activity 
of mice. 
 
 
MATERIALS AND METHODS 
 
Plant  
 
Fresh and matured leaves of A. cordifolia (Schum. and Thonn.) 
Müll. Arg. (Euphorbiaceae) were collected in Abidjan along the old 
Bingerville road and verified by a botanist expert (Professor Ake 
Assi, Department of Botany, University of Abidjan). 
 
 
Animal  
 
White mouse of Mus muculus race, of either sexes, weighing 
between 20 and 27 g were used. They were fasted 18 h before the 
experiment with water ad libitum. Five homogenous weight set of 6 
mice were set up. 
 
 
Preparation of lyophilized aqueous extract 
 
Shade dried leaves were crushed in a Ritscher grinder (SM 100 
serial from Germany) and 50 g of the obtained powder was then 
macerated for 48 h at 25°C in a glass balloon containing 500 ml of 
distilled-water. The obtained aqueous extract was then filtered and 
freeze-dried with a Telstar Gryodos-80 labeled freeze-drier. The 
freeze-dried product was kept in a glass flask at a 4°C temperature. 
 
 
Chemical substance used 
 
Chlorpromazine (LARGACTIL ®) Laboratory EurekaSanté was 
used as reference standard.  
 
 
The study of spontaneous movements in activemeter 
 
The method of Pérez et al. (1998) was used for the study of 
spontaneous movement. The activemeter AM 1051 operates by 
using infrared light ray to detect movement. There are two sets of 
light ray, placed in two separate and independent matrices, one 
above and one below. The lower ray is used to detect the normal 
movement and the upper ray to detect if the animal rises. The 
sensor operates by detecting the number of times that the ray 
changes from "obstructive" to "non-obstructive" and vice versa. In 
this way more spontaneous movements can be recorded like rapid 
movements, rapid straightening up, and duration of all spontaneous 
movements. Five (5) uniform batches of six (6) mice were formed. 
One batch served as controls lot and received saline (10 ml/kg 
body weight), another batch received chlorpromazine (2 mg/kg 
body weight), reference chemical substance used in this study. The 
other three batches each received different doses of our extract 
(625, 1250 and 2500 mg/kg body weight.). The mice were placed 
one after the other in the Activity Monitor AM1051, 30 min after 
treatment and rapid movements, rapid straightening up, and du-
ration of all spontaneous movements are recorded for a period of 5 
min. The operation was repeated three times at intervals of 30 min. 
 
 
The study of exploratory activity of mice 
 
The method of Boissier and Simon (1967) was used for the study of 
exploratory activity of mice. A hole board with holes measuring 40 ×   
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40 cm by 2.2 cm thickness and with 16 equidistant holes, 3 cm in 
diameter fitted with infrared transmitters and receptors. These 
transmitters and receivers are incorporated in miniature into walls of 
each hole and around the board. The board is connected to a 
counter which automatically detects the exploratory movements of 
mice. Out of the five lots, one lot was used as control and received 
normal saline solution (10 ml/kg body weight), another batch 
received reference chemical substance, that is, chlorpromazine (2 
mg/kg body weight), the other three batches were administered 
each an increasing dose of the extract (625, 1250 and 2500 mg/kg 
p.o). The mice were placed one after the other in the middle of the 
board after 30 min of treatment and the number of holes explored 
within 5 min was recorded. The procedure was repeated every 30 
min for 90 min. The average number of holes explored was 
calculated. 
 
 
Statistical test 
 
The comparison of these means was performed using Student’s t 
test. The difference between two averages is considered significant 
if the calculated t is greater than or equal to t theoretical risk α = 
5%. 
 
 
RESULTS 
 
The differences recorded in activities with the extract at 
dose 625 and 1250 mg/kg body weight is not significantly 
different from each other, which will not present the 
results obtained with the dose of 625 mg/kg body weight. 
 
 
Spontaneous movements 
 
These spontaneous movements were represented by the 
number of rapid movements (Figure 3) and the number of 
rapid straightening up (Figure 2). The duration of all 
spontaneous movements is as shown in Figure 1. 
Overall, we noted that the mean obtained for the control 
lot were higher than all other lots. There was a significant 
decrease in mean and duration of spontaneous 
movements of mice at 2500 mg/kg body weight of extract 
as compared to the control from 30 to 90 min, but still 
higher than the mean obtained with lot receiving 
chlorpromazine. 
 
 
The exploratory activity 
 
The number of holes explored in 5 min by different 
groups of mice is shown in Figure 4. Herein, it was noted 
that the mean of the control group was higher than all 
other lots. From 30 to 90 min, the number of explorative 
activities decreases. There was a significant decrease in 
explorative activities of mice receiving the extract at 2500 
mg/kg body weight dose as compared to the control, but 
remain superior as compared to the mean obtained with 
mice receiving chlorpromazine.  
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Chlorpromazine 
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Physi logic solution 
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Figure 1. Effects of Alchornea cordifolia extract 30, 60, and 90 min after force-feeding along the 
activity duration. Histograms represent the rapid movements average ± SEM of 6 experiments of 
each lot. *Significant difference as compared to the physiological solution lot P<0.05 of t test of 
student. 
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Figure 2. Effects of Alchornea cordifolia extract 30, 60, and 90 min after force-feeding on rapid 
straightening-up. Histograms represent the rapid straightening average ± SEM of 6 experiments 
of each lot. *Significant difference as compared to the physiological solution lot P<0.05 of t test 
of student. 
 
 
 
DISCUSSION 
 
Alchornea cordifolia is used in Africa traditional medicine 
in the treatment of various neurological and psychiatric 
disorders. This study is meant to highlight the importance 
and efficiency of traditional medicine by revealing the 
anxiolytic activity of A. cordifolia leaves. Spontaneous 
movements and exploratory behaviour of  mice  were  the  
measures used to assess the central nervous system 
depression of A. cordifolia. The study of spontaneous 
movements in mice (rapid movements, rapid 
straightening up, duration of all spontaneous movements) 
using the activity meter is used to measure exploration 
and voluntary locomotion in a new environment and in a 
limited space. Spontaneous movements’ particularly ra-
pid straightening up reflect an excitement of  the  nervous 
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Figure 3. Effects of Alchornea cordifolia extract 30, 60, and 90 min after force-feeding on rapid moving. 
Histograms represent the durations average ± SEM of 6 experiments of each lot. *Significant difference as 
compared to the physiological solution lot P<0.05 of t test of student. 
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Figure 4. Effects of Alchornea cordifolia extract 30, 60, and 90 min after force-feeding over the number of 
explored holes. Histograms represent the durations average ± standard duration, n=6 for each lot. 
*Significant difference as compared to the physiological solution lot P<0.05 of t test of student. 
 
 
 
system in mice. The decrease in spontaneous 
movements is the result of a decrease in the excitability 
of the central nervous system or central depressant effect 
(Mansur et al., 1971; Morais et al., 1998). In this study, all 
spontaneous movement in mice, rapid movement (Figure 
3) rapid straightening up (Figure 2) and the duration of 
activity (Figure 1) were reduced as a result of A. cordifolia 
extract administration at a dose of 2500 mg/kg body 
weight. These effects are similar to those of 
chlorpromazine, a psycholeptic agent depressing the 
central nervous system.  
This molecule is used in the treatment of agitation and 
aggression in the acute or chronic psychotic states. Thus 
Alchornea cordifolia could possess central nervous 
system depression activity. The hole board test provides 
a simple method to measure the response of an animal to 
an unfamiliar environment and is widely used to assess 
emotionality, anxiety and/or response to stress in animals 
(Takeda et al., 1998) showed that the exploration of holes 
by the mouse reflect changes in the emotional state of 
the animals. Thus, the hole board test is a measure of ex-
ploratory behavior of animal, and substance  that reduces  
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this behavior is responsible for the anxiolytic activity (File 
and Wardill, 1975; Pellow et al., 1985). The ability of 
exploration can be seen as a sign of anxiety (Crawley, 
1985) although it is difficult to dissociate from locomotive 
activity. Our results may reflect anxiolytic activity of A. 
cordifolia as a reduction was observed in the exploratory 
behavior of mice treated with the extract at 2500 mg/kg 
body weight similar to that observed with chlorpromazine. 
This fact reinforces the hypothesis of anxiolytic activity 
described earlier by reducing spontaneous movements 
measured in the activemeter. Many neurotransmitters 
influence spontaneous movements in mice.  
These include the gamma-aminobutyric acid (GABA), 
opioids, dopamine receptors (Walting and Keith, 1998). 
A. cordifolia could interact with these mediators. GABA-A 
is the main mediator of anxiety in the central nervous 
system. In addition to anxiety, it is involved in other 
physiological functions related to behavior, and various 
psychological and neurological disorders such as 
epilepsy, depression, Parkinson's syndrome and 
Alzheimer's disease.  
The anxiolytic properties of A. cordifolia observed in 
this study could be explained by an interaction with the 
metabolism of GABA-A. This hypothesis could be in 
agreement with the results of Pedersen et al. (2009). In 
fact they explained that A. cordifolia has an affinity for the 
benzodiazepine binding site on GABA-A receptors 
without activating or inhibitory activity demonstrated on 
these receptors. 
Several phytochemical constituents have proved to be 
inhibitors of spontaneous movement in mice. These are 
flavonoids, which have also shown an affinity for the 
benzodiazepine receptor (Pedersen et al., 2008) and 
saponins (Wagner et al., 1983; Dubois et al., 1986). 
Knowing that A. cordifolia contains in its leaves saponins 
(Adjanohoun, 1994) and flavonoids (Manga et al., 2004), 
the anxiolytic activity observed in this study could be 
partly due to these phytochemical constituents. 
A. cordifolia leaves could therefore have a depressing 
effect on the central nervous system which justifies its 
uses in traditional medicine in the treatment of 
neuropsychiatric disorders. 
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